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Abstract 
Introduction: Transdermal electroporation involves the application of high voltage 
electrical pulses for microsecond to millisecond duration to produce reversible 
increase in permeability of skin. It can provide an alternative route to intravenous 
injection for the fast delivery of macromolecules molecules such as proteins and 
peptide drugs in clinically effective amounts for the patient. However, the 
mechanism of electroporation and its safety are unclear. Hence, electrical 
parameters for delivery of individual drugs have to be chosen empirically or by 
careful optimization. 
Objectives: To carry out optimization of electrical parameters using fuzzy rat skin 
tissue in vitro for delivery of terazosin hydrochloride (TRZ), followed by use of these 
parameters in live fuzzy rats (in vivo), to study their safety and effectiveness. To 
design in vitro and in vivo tests to predict the safety of this technique. 
Materials: Side-by-side diffusion cells were used for in vitro and in vivo studies. 
Ag/AgCI electrodes of different areas were used to deliver the exponentially 
decaying electroporation pulses from a Gene Pulse~ (BioRad Laboratories, USA). 
Fuzzy rats and freshly excised full thickness skin from fuzzy rats were used for in 
vivo and in vitro studies respectively. 
Methods: Pulse length and rate of pulsing were evaluated with respect to their 
ability to reverse the increased permeability caused by electroporation. The 
correlation between TRZ concentration and increase in electroporative delivery was 
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studied. Based on above studies optimal parameters were chosen to deliver TRZ 
in vivo. Their safety and effectiveness were compared to delivery without 
electroporation (control). Pharmacokinetic parameters were estimated by giving 
drug intravenously and subcutaneously. In vivo impedance recovery of skin after 
electroporation to pre-electroporated state was studied to predict safety. Similarly, 
uptake of glucose by skin with or without electroporation was studied to predict 
change in viability (damage) in vitro. Finally, electrodes of different area were 
characterized in vitro with respect to the electrical parameters. These parameters 
in conjunction with the in vitro and in vivo drug delivery and safety studies would 
throw some light on the mechanism of electroporation and the effect of electrode 
area on drug delivery and safety by electroporation. 
Results and discussion: If electroporation is completely reversible then the rate 
of transport of drug through the skin after stopping electroporation pulses should 
be the same as that through non-pulsed skin. Using this method an applied voltage 
(Uelectrode,o) of 400V, a pulse length of 20 millisecond and a rate of pulsing of 10 pulse 
per minute (ppm) were found to be relatively safe and delivered significantly higher 
drug compared to passive drug delivery. Increased donor concentration gave higher 
delivery and may help in reducing exposure to higher electrical conditions to 
produce same amount of drug delivery. In vivo studies showed that TRZ can be 
delivered safely and effectively with electroporation. However, the effect of 
electrode area needs to be studied further. Pharmacokinetic studies indicated depot 
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formation within skin after electroporation and this could be due to limited blood 
flow to the skin. In vitro biochemical studies showed a lag time in lactate production 
when a very high voltage electroporation pulse was used and there was a general 
stimulation of lactate production (as a result of glucose utilization) after 
electroporation compared to non-electroporated skin. The lag time may be used to 
predict damage due to electroporation. In vitro electrode characterization studies 
gave considerable insight into the observed drug delivery profiles and the 
differences in safety profiles between the different electrodes. In vivo impedance 
studies showed that complete recovery of skin impedance after electroporation 
might take hours to days. Recovery was faster with shorter pulse lengths and lower 
number of pulses. 
Conclusions: An applied voltage of 400 V, 20 pulses of 20 millisecond at the rate 
of 1 0 pulses per minute with 1 0% TRZ in contact with skin and using a small area 
electrode was found to be relatively safe and effective for delivery of TRZ in vitro 
and in vivo, with higher delivery for higher electrode area as predicted. The in vitro 
electrode characterization experiments could explain some of the observed 
differences between the drug delivery by different electrodes and in vitro viability 
studies could predict damaging electrical conditions. In vivo impedance studies 
showed that the parameters which can cause appreciable recovery of impedance 
after electroporation, are those that have not shown to deliver appreciable amount 
of drug in vitro, at least by electroporation alone. New electrode designs or new 
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methods will have to be devised to increase safety of electroporation before 
electroporation can be considered useful or tested on humans. 
-v-
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1.0 Introduction 
1.1 Drug Delivery Systems : 
Advances in biological sciences have provided newer insights in various 
physiological and pathological processes. This has led to the discovery of large 
number of new drug molecules to mitigate, prevent or treat diseases. The 
biotechnology area has been growing fast too, resulting in the introduction of new 
generation of therapeutic moieties viz: proteins and peptides. The recent 
completion of the human genome project will likely lead to identification of genetic 
links to many diseases. Indirectly this will fuel the discovery of many new functional 
proteins and peptides which could then be used to treat the condition (Saba, 2001 ). 
Enzyme susceptibility is one of the challenges of these therapeutic entities that 
make conventional dosage forms unsuitable for their delivery. Presently, parentral 
route is the main delivery system for the peptide and protein moieties but they are 
painful, invasive, and expensive. Thus, many companies and researchers have 
been investing in research for alternative drug delivery systems (Cleland, 2001 ). 
Combined efforts of many scientists has led to the development of a vast 
array of non-invasive drug delivery systems capable of delivering proteins and 
peptides. Among the many drug delivery systems which have made to the market 
or are in clinical trials, are the transdermal drug delivery systems. In this thesis 
effort is directed towards optimizing transdermal drug delivery using electroporation 
as a physical means of enhancement of drug delivery. 
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1.2 Transdermal drug delivery systems : 
This route of drug delivery offers many advantages over conventional 
dosage forms. It is easily accessible, non-invasive, avoids the hepatic first-pass 
metabolism, provides better rate control and might also lead to fewer side-effects 
· due to the elimination of peaks and valleys of the conventional dosage forms. It also 
provides a less harmful environment for enzyme and pH susceptible drugs like 
proteins and peptides compared to the conventional dosage forms. This might lead 
to increase in bioavailability of some of the drugs. The skin behaves like a depot 
especially for the lipophilic drugs. Thus, some drugs having short half-lives can be 
delivered for extended periods like an IV infusion. 
Local and systemic delivery of drugs by topical route have been used for 
decades. However, the present popularity of this route for controlled clinically 
effective systemic delivery of drugs was triggered by the introduction of transdermal 
scopolamine patches for the treatment of motion sickness in 1981 followed by 
introduction of the transdermal nitroglycerine patches in 1982 (Chien, 1987). Since 
then a number of transdermal products have made it to the market (Flynn, 2002). 
Presently, molecules upto 178 KDa have been delivered with transdermal 
drug delivery systems (TDDS) (Prausznitz, 1997). Macromolecules pose a real 
challenge for TDDS. However, this has only aggravated the need for better 
techniques and delivery enhancers. Many physical and chemical enhancers have 
been utilized to breach the formidable barrier of the skin's outermost layer- stratum 
2 
corneum (SC). Improved understanding of the SC's barrier structure and function, 
and the ability to breach it has led to better success rates in TDDS (Prausnitz, 1997 
and Barry 2001 ). 
1.3 Skin Structure and Composition : 
Skin of an average adult covers approximately 2 m2 and receives one third 
of the blood circulating through the body and as such provides an excellent portal 
for delivery of drugs (Jacob, 1970). However, the barrier to percutaneous delivery 
lies within the SC -the outermost 10-15 ~m thick layer of skin. It serves to keep 
foreign substances out and water in. 
With regards to drug delivery, it is to be noted that the barrier properties of 
skin vary greatly with anatomical site, age, phenotype of individual cells, the 
number and type of glands, the sebaceous secretions and the degree of 
vascularization. The following is a general discussion on structure and composition 
of the skin which will help in the better understanding of the skin barrier. 
1.3.1 Anatomy of skin as relevant to drug delivery : 
The skin is divided into the fbllowing major layers: the epidermis, dermis and 
hypodermis, located below the dermis. The epidermis and dermis are separated 
by the basement membrane. The epidermis consists of viable tissue supplied by 
blood vessels but devoid of nerves, a feature which is still debated by many 
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scientists (Hillinges, 1995). The dermis which lies below the epidermis also contains .. 
living cells, in addition nerves and blood vessels. 
The epidermis consists of five layers. The bottom-most layer consists of fast 
dividing keratino~ytes and is called basal layer. These cells then migrate upwards 
to mature into spinous cells forming spinous layer. Then into granular cells forming 
the granular layer. Then form the stratum lucidum and finally undergo edge-to-edge 
fusion to form the sheet like layer made up of the flattened, keratinized and dead 
cells of the SC. As the cells mature from the basal layer to the SC, a number of 
existing cellular components have to be degraded, e.g. proteins or lipids, by the 
lytic enzymes. These enzymes can also degrade topically applied drugs. Thus, the 
SC represents the physical barrier to TDDS, whereas the viable epidermis the 
enzymatic barrier. The dermal-epidermal junction is convoluted and forms papillae 
which enormously increase the surface area of contact between these two layers. 
It is relatively permeable to molecules upto 40 KDa (Schaefer, 1996) 
The dermis consists of loose connective tissue and contains collagen and 
elastic fibers as well as various cells including fibroblasts, mast cells, macrophages 
and lymphocytes. The blood vessels and lymphatics are also located here. Finally, 
the epidermal appendages such as hair follicles, sweat glands and sebaceous 
glands are also embedded in this tissue. 
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1.3.2 Structure and composition of SC : 
The importance of SC as a barrier cannot be over-emphasized. Physically 
stripping off the outmost layer of skin increases water and drug permeability by 
several fold ( Scheuplein, 1971 and Schaefer, 1982) and this simple experiment can 
be used as a proof of SC as a barrier layer. In another study, it was shown that the 
transepidermal water loss (TEWL) increased with the sequential removal of SC 
(van der Valk, 1990). It is imperative that the SC structure and composition be 
understood to achieve better success rates by the transdermal route. 
Improved visualization techniques such as atomic force microscopy, freeze 
fracture and electron microscopy, attenuated total reflectance- Fourier transform . 
infra-red spectroscopy (ATR-FTIR), differential scanning calorimetry (DSC)have led 
to a better understanding of the structure of epidermis in general and more 
specifically the SC (Turner, 1997 and Jadoul, 1999,). Advances in various other 
scientific fields have helped characterize the chemical composition and the physical 
nature of this layer. 
Structurally the SC is likened to the "brick and mortar'' with the bricks made-
up of flattened keratinocyte cells, also called corneocytes, filled with protein -
keratin, which provides strength and chemical resistance. These cells are · 
surrounded by intercellular lipid layers which form the "mortar''. The keratinocyte 
bulk is considered to be relatively permeable compared to the highly impermeable 
lipid layers surrounding it. This inter-cellular layer can be resolved into further 
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alternating lipid and aqueous domains. There are about 15-20 keratinocyte layers 
and thus about 75-100 lipid bilayers in the SC. Typically each of these layers has 
4-51ipid layers alternating with 4-5 aqueous layers as revealed by freeze-fracture 
electron microscopy (Van Hal, 1996). These aqueous layers reduce the diffusional 
pathlength for hydrophilic molecules within the SC which explains the increased 
permeability due to occlusion. 
·tntercellular r 
space L 
Lipid Aqueous 
Transcellular route 
Cholesterol Ceramide Lipid ?? Keratin 
Glucosylceramide 
Figure 1.1 :Structure of SC and its components. (Reproduced with permission 
from -Skin barrier principles of percutaneous absorption by Schaefer H, 
Redelmeier TE, Karger and Basel, 1996, pp78) 
Although, the keratinocytes provide the bulk of the SC, the intercellular lipids 
form the only continuous domain within the SC, following a tortuous path around 
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the keratinocytes. This feature of the lipid domain makes it the most important 
component for providing the barrier function. Selective removal of SC lipids by 
using organic solvents like acetone has the same effect as selective tape stripping 
(Potts, 1991) which provides additional proof for the importance of SC lipids in 
providing barrier property to the skin. However, several pathological conditions 
which alter the structural proteins within the corneocytes, also increase dermal 
permeability. Care has to be taken when interpreting the determinant of SC barrier 
function. 
1.3.3 Chemical composition of the SC barrier layer: 
Just as the SC evolves from the epidermis as a distinct layer, the cells within 
the SC also undergo changes as they move up the SC during the desquamation 
process. The uppermost 3-41ayers are called stratum disjunctum and the lowermost 
3-4, stratum compactum. These layers differ in their composition and morphology 
of the lipids and hence an analysis of the average chemical and material properties 
of the SC would be an oversimplification. 
The SC is a rather dry layer compared to other physiological membranes 
with an approximate water content of 15 %, proteins 70 %, and 15 % lipids. This 
is considerably different from the rest of the epidermis which has approximately 
70% water, 15 % protein, 5 % nucleic acid and 5 % lipids. The decreased water 
content in the SC is attributed to the hydrolysis and degradation of nucleic acids, 
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proteins, and phospholipids leading to a decrease in the number of chemical groups 
that can bind to water. Though most of the water in the SC is present within the bulk 
corneocytes, the intercellular lipid domains also contain some water. Artificially 
hydrating the SC to more than the physiological levels (above 30-40%) leads to 
swelling of the corneocytes (Blank, 1985 and Mak, 1991) and progressive loss of 
barrier function (Bodde, 1990 and Barry, 1983). The corneocytes contain many low 
molecular weight polar compounds (amino acids, sugars etc) collectively referred 
to as the natural moisturizing factors (NMF) which bind to water. 
A significant gradient of phosphorus and potassium exists within the SC, 
decreasing from the stratum com pactum as it reaches the stratum disjunctum where 
it is the lowest. Similarly, there exists a gradient of calcium too, however, the 
calcium concentration is the highest in the outermost stratum disjunctum and 
reduces in the deeper layers of SC. Mauro et al (1998), have shown that barrier 
perturbation abolishes the gradients of calcium and potassium within the SC. The 
phenomenon responsible for the presence of this gradient or its absence with the 
barrier perturbation is unclear. However, several processes during the epidermal 
maturation require calcium ions viz: conversion of profilaggrin to filaggrin, activation 
of serine proteases and transglutaminases for programmed cell death (Mauro, 
1998). 
The corneocytes contain the bulk of the proteins within the SC. Mainly, they 
contain keratin associated with some filaggrin, surrounded by a cornified envelope. 
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This envelope is stable to chemical treatment. The keratins have an endothermic 
transition temperature of 95° C (Golden, 1986). The cornified envelope is made up 
of equimolar concentration of high molecular weight proteins (80% by mass) and 
lipids. The proteins which evolve from degradation of organelles, as well as 'the 
proteins and lipids of the viable epidermal cells are resistant to proteases. These 
proteins are cross-linked by three types of bonds which make them highly resistant 
to lysis by proteases. The lipids within the cornified envelope are covalently bound 
to the proteins and may interact with intercellular lipids to decrease discontinuities 
or provide barrier function to the corneocytes. Ceramides are the major lipids of the . 
cornified envelope. Corneodesmosomes are proteins which cross-link the 
corneocytes and provide mechanical strength to the SC. Their gradient decreases 
in the upper layers of SC, emphasizing their importance in desquamation. Hydration 
can influence the corneodesmosome degradation and therefore increase 
permeability (Rawlings, 1995). 
The intercellular lipids within the SC have a different composition and 
morphology compared to that of cellular membranes. They also differ from the lipids 
present within the viable epidermis in their composition. The intercellular lipids 
contain equimolar concentrations of ceramides, free fatty acids and cholesterol. 
These lipids differ from membrane lipids in that, they have very 'small' polar head 
groups which can potentially bind to w~ter, thus, the low water content of SC. These 
lipids are also predominantly neutral in nature in contrast to cellular lipids which are 
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predominantly anionic. The SC also contains lipids derived from sebaceous 
secretions, however, these are present mostly in the upper stratum disjunctum 
layer. Although, these lipids can influence SC lipid composition, they do not 
contribute to the barrier property of SC, probably because these lipids are not 
ampipathic and hence do not get incorporated into the lipid bilayers. However, they 
change the surface concentration of lipids and may get incorporated into topical 
applications, diluting them and thereby influencing percutaneous absorption. 
The SC is shown to have four transition temperatures by differential scanning 
calorimetry (DSC) viz; 35, 65, 80 and 95°C (Golden 1986). As pointed out earlier, 
the 95°C transition has been assigned to keratins, since the removal of lipids by 
solvents does not abolish this transition temperature. The low· temperature 
transition of 35°C, has recently been proposed to be due to minor lipid component 
or to that having a low enthalpy (Gay; 1994). The 65°C transition point was 
attributed to SC lipids, analyzed by selectively extracting these lipids. However, 
these extracted lipids did not show the 80°C transition, which has been proposed 
to be due to the specific morphological ordering or protein-lipid interaction within 
the intact SC, These phase transition temperatures differ from that of cellular 
membranes which have a transition at -20°C, indicating a liquid crystalline state of 
these membranes. The lateral diffusion of lipids within the layers increases from a 
solid-crystalline ·to gel to liquid crystalline states, so does the mo~ecular 
permeability. Thus, the SC with high transition temperature can ·be considered in 
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a more ordered state or in a solid-crystalline state and contributing to its unique 
barrier properties. This highly ordered state also permits the study of SC using X-
ray crystallography. Thus changes caused in SC can be analyzed using DSC or X-
ray crystallography. 
1.3.4. Other features - Enzymes in the SC: 
The SC is not as 'dead' as it seems. Metabolic processes do go in the SC, 
especially at the junction of the viable epidermis and the stratum compactum. 
Formation of precursor lipids to the intercellular lipids requires enzymes such as 
sphingomyelinase, phospholipases; acid lipases, beta-glucocerebrosidases, 
proteases, acid hydrolases and acid phosphatases. The degradation of 
corneodesmosomes during desquamation process also requires the presence of 
proteases. Hence the enzyme aCtivity may be present in the upper layers of SC too. 
Hydrolases required for hydrolysis of cholesterol esters may also be present in the 
stratum disjunctum. These proteases and hydrolases in the SC need to be 
considered seriously when using a transdermal system for delivering proteins and 
peptides. Due to the ability of skin to form depot for drugs, they might get exposed 
to significant levels of lytic enzymes reducing the bioavailability through skin. 
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1.3.5 Electrical properties of the skin: 
Waters is a good conductor of electricity. The current in such an electrolyte 
is carried by ions. Such a system provides "resistance" or obstruction to the ion 
flow. The skin also conducts electricity. In a complex biological tissue like skin, the 
current is carried by ions through the hydrophilic pathways. Under direct current the 
skin exhibits resistance only. However under alternating current, when the 
frequency of current keeps changing, the lipid milieu of skin also starts taking a 
significant part. The lipids within the skin act like capacitance- or parts which store 
current. Capacitances behave differently with varying frequency of current. 
Measuring the resistance of the skin in such a case will not provide the complete 
picture. Impedance which is a measure of the resistive and capacitative 
components of a circuit would be more meaningful measure. This also means that . 
measuring the impedance of skin would give us an idea of the barrier to drug 
delivery (ion transport) across skin. Conversely if due to any reason there is a 
change in drug delivery (for example application of electroporation pulse to skin) 
it should be reflected by a change in the impedance component of the skin. 
Impedance measurement involves application of fixed voltage with varying 
frequency current and measuring the potential drop across the skin. The typical 
impedance spectrum of skin shows the real impedance on Y -axis which represents 
the resistive pathways (e.g. hair follicles, sweat ducts, aqueous layers) and 
imaginary impedance on X-axis which represents the capacitive pathways (e.g. lipid 
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milieu of skin) over a range of frequency. 
Since there could be various pathways, the impedance plots of skin can be 
interpreted in various ways. Based on impedance plots various equivalent circuits 
of skin have been proposed. The most simplest equivalent electrical circuit 
representing the electrical behavior of skin is shown in Figure 1.2A. Basically the 
skin is considered to be a resistor and capacitor in parallel with a resistance in 
series to account for the properties of the electrolyte. (Rosendahl, 1945 and 
Yamamoto, 1976). 
R 
c 
--Solution 
--- Solution resistance 
resistance 
(A) Simplest model (B) Includes two pathways 
LC = Lipid-Corneocyte and 
A = Appendageal 
Figure 1.2 : A simple electrical equivalent circuit for skin's electrical behavior. 
R = resistance and C = capacitance. 
The above model is adequate for low voltages applied to skin, however, in 
more specific studies, two pathways for applied electrical current have been 
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reported, one through the lipid-corneocyte matrix and another through the 
appendages (Piiquett, 2000b and c). Hence, the electrical circuit would now have 
two parallel components each containing a resistor and capacitor in parallel (Fig 
1.28). Many such modifications can be drawn to reflect the changes in skin's 
electrical properties. 
However, for general purposes, the resistance of the skin can be used as a 
predictor of skin permeability. Normal skin has a resistance in the order of 5-100 
Kohm.cm2 upto a temperature of 60°C. Increasing the temperature beyond that to 
about 60-70°C, leads to a dramatic drop in this resistance (Oh, 1993). This has 
been attributed to the melting or phase transition of the intercellular lipids in the SC 
which can lead to a dramatic increase in the permeability to ions and electrolytes. 
Similarly a very low resistance in an in vitro skin preparation indicates an obvious 
leak. Puncturing the skin with a hypodermic needle also can cause a dramatic drop 
in the skin resistance (Prausnitz, 1999). Thus, the resistance of skin cannot be 
taken as a single measure of barrier disruption. However, being the fastest and 
most convenient method, it is often used to predict the skin's permeability 
(DeNuzzio, 1990). 
1.4 Pathways for Percutaneous Penetration: 
Three percutaneous penetration routes have been proposed to exist: (i) 
appendageal, (ii) intercellular and (iii) transcellular (Figure 1.3). 
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(i) Appendageal route is also called as the shunt pathway. It involves the hair 
follicles and sweat gland ducts. Permeation through the shunts avoids the 
intercellular lipids of the SC. However, the area covered by the shunts is less than 
1% (Scheuplein, 1971) of the total skin area. Hence, even if the permeability of this 
route is higher, the major pathway will be across the SC. Drug permeating through 
this route directly reaches the dermis, where the bases of these follicles as well as 
the vascular network are located. Thus, it could be considered as the shortest and 
fastest route to vascular delivery for topically applied compounds. Many studies 
have shown that this route is important in determining molecular flux in transdermal 
iontophoresis (Scott 1993, Cullander 1991 a,b and 1992,Burnette, 1988). 
(ii) Intercellular route involves the tortuous route through the intercellular lipid 
domains. Diffusion of molecules across a lipid bilayer would be energetically less 
favorable than the diffusion within the bilayer. This is one of the main reasons which 
favors the tortuous pathway( Devaux, 1993). Moreover, using the partition coefficient 
and lag time, the water penetration pathway was found to be around 50 times longer 
than the thickness of the SC, which strongly suggests that the tortuous pathway may 
dominate (Potts, 1991 ). Another explanation for diffusion of polar molecules is the 
presence of alternating lipid and aqueous layers within the intercellular domains. 
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Transcorneal 
penetration 
·~--+____,...__~~ Horny layer 
Epidermis 
Dermis 
Blood . vessel 
Blood vessel 
Figure 1.3: Pathways of transdermal delivery (Reproduced with permission from -
Skin Barrier Principles of percutaneous absorption by Schaefer H, Redelmeier 
TE, Karger and Basel, 1996, pp78) 
Such a conclusion was a combination of two observations, one that water seems to 
follow the tortuous path through the intercellular domains as detected by FTIR 
(Potts, 1990) and the second that the loss of ordering within this lipid domain leads 
to increased water loss. Thus, these tortuous aqueous and lipoidal pathways have 
been accepted as the most favorable routes for topically applied compounds. 
(iii) Transcellular pathway: Although, the penetration of compounds require that they 
traverse the lipoidal domain, it does not exclude the possibility that they can enter 
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the corneocytes which contain hydrophilic proteins. Hydration or occlusion leads to 
swelling of the corneocytes, thus water may enter the corneocytes, increasing the 
permeation compounds. Even large molecules like mercury could penetrate the 
corneocytes in the upper stratum disjunctum layer of the SC suggesting that the 
corneocytes within this layer could be more permeable. Thus, these pathways are 
not mutually exclusive and permeation is determined by the area of the pathway, 
partitioning and diffusivity of the compound within each pathway. 
1.5 Strategies to enhance transdermal drug delivery: 
To reach the systemic circulation a topically applied drug must permeate the 
SC and epidermis to reach the dermis, where the vascular network is located. For 
compounds with a molecular weight of less than 500 daltons, the SC seems to be 
relatively permeable. However, as the molecular weight is increased, the partition 
coefficient, between the hydrophobic and hydrophilic layers of skin, becomes rate 
limiting. The permeability seems to increase with increase in the partition coefficient. 
Thus the rate-limiting barrier in the SC is lipoidal in nature. For hydrophilic drugs the 
partitioning into this barrier will be rate limiting, and for lipophilic drugs the 
partitioning out of this barrier would be rate limiting. This also presents a strong 
possibility of depot formation for lipophilic compounds within the SC. Thus, an 
enhancer can act in three ways (i) to increase the partitioning of compounds into SC, 
(ii) to increase diffusivity of compound from the SC or (iii) to cause a change in the 
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penetration pathway. Classically, strategies to enhance transdermal or topical drug 
delivery have been studied based on whether these enhancers cause chemical 
changes in skin (SC) or physical changes. This system of classification still exists 
and is used in the following discussion. 
1.5.1 Occlusion: It is the application of an impermeable barrier layer to skin, which 
decreases TEWL. This can lead to an increased water content in the SC up to 
300%. Studies have shown that this water is mainly taken up inside the corneocytes. 
Also, formation of small water channels has been proposed which reduces the 
diffusional pathlength of mainly hydrophilic compounds, and also lipophilic and 
amphiphilic compounds (Bucks, 1989). 
1.5.2 Chemical enhancers : These can act in any of the three ways discussed 
earlier to increase transdermal drug delivery. Mainly chemical enhancers such as 
dimethyl sulfoxide and azone can disrupt the lipids in SC. Surfactants have also 
been used to increase penetration of drugs. Non-ionic surfactants are preferred to 
ionic since these have less potential to cause irritation. Concentration of surfactants 
has to be regulated such that aggregation to micelles is prevented. Monomer 
incorporation into SC lipids would not be possible with concentrations reaching 
critical micelle concentration. These agents in their monomer state, are 
hypothesized to get incorporated in the intercellular lipid domains providing 
additional medium within which an agent can diffuse into, reducing the transit time 
of the drug across the SC (Walters, 1988 ). Similar results were also evident with 
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oleic acid and other fatty acids which provided alternate pathways generally for 
diffusion of lipophilic compounds (Mak, 1990 and Ongpipattanakul, 1991 ). 
Evaporation of a chemical enhancer like ethanol might cause saturation of 
drug and thereby increase the thermodynamic activity of the drug, which in turn 
could indirectly contribute towards enhancement (Hadgraft, 1989). However, 
chemical enhancers are more likely to cause irreversible changes in the SC, some 
of them may cause irritation, and could potentially get absorbed and produce 
unwanted pharmacological effects themselves (Guy 1996). These factors make them 
very unlikely candidates for approval from United States Food and Drug 
Administration (USFDA) or Health Canada. 
1.5.3. Physical enhancers: 
Many methods exist to alter the physical properties of the skin or specifically 
the SC. Although, tape stripping can be used to selectively remove layers of SC 
causing a modest increase in the permeability, it does not completely eliminate the 
barrier properties of the skin. It has however, been used as a tool to study the 
mechanism of action of other enhancers. 
1.5.3.1 Iontophoresis: 
This method involves the use of electric current to deliver drugs across the 
SG. Briefly, a few milliamps of electric current is applied using an electrode of 
opposite charge to that of an ionic drug to repel the drug into the skin. However, 
eiectro-neutral water soluble drugs can also be delivered due to electro-osmosis of 
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water. Controlling the current can help control the delivery, hence this method has 
an excellent potential to be used as a controlled drug delivery method. As discussed 
earlier, the primary route of iontophoretic drug delivery is shown to be the 
appendageal route. 
Peptides like calcitonin containing upto 32 amino acids have been delivered 
successfully (Greene, 1996 and Santi, 1997). The delivery of oligonucleotides has 
also been shown( Oldenburg, 1995 and Brand, 1996). Most importantly, this method 
has been extensively studied as an alternative delivery method for insulin. However, 
the success of this technique to deliver insulin remains questionable. Some of the 
difficulties can be attributed to the properties of insulin such as, its isoelectric point, 
which lies in the range of skin pH and can cause its precipitation in the SC and its 
ability to associate to form hexamers can cause a huge increase in the molecular 
weight making transdermal transport very difficult (Banga, 1999). The onset of action 
is not as fast as an IV injection. As a result the drug has to be given over minutes to 
hours to get significant rates of delivery. Nevertheless, significant progress has been 
made over the years. Wearable devices or miniature devices which can be attached 
to the body for long periods of time to provide programmed drug delivery have been 
developed and look promising (Banga, 1998a). Another important application of 
iontophoresis has been "reverse iontophoresis" for analysis of metabolites in the 
interstitial fluids which can act as bio-feedback mechanism for various drug delivery 
devices (Giikfeld, 1989). Since the first reporting of this technique, research has 
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progressed very fast. Recently the US-FDA has granted permission to Cygnus, Inc 
(Redwood city, CA) for the marketing of Glucowatch TM in the USA (FDA, 2001 ). This 
device can monitor the body glucose levels by reverse iontophoresis. The glucose 
here is extracted at the cathode by electroosmosis. This device can be used to 
regulate insulin delivery using iontophoresis. 
Iontophoresis is being routinely used in the diagnosis of cystic fibrosis in 
hospitals (Warwick, 1986). Alza® corporation, CA, USA is also in the process of 
developing a transdermal iontophoresis system for the delivery of fentanyl for local 
anaesthesia (Gupta, 1999). While many drugs or even peptides can be delivered at 
therapeutic rates, iontophoresis cannot deliver very high molecular weight peptides 
or proteins and oligonucleotides. This has led to combining iontophoresis with other 
enhancers. Chemical enhancers, like ethanol pretreatment followed by 
iontophoresis has led to significant enhancement of insulin delivery compared to 
iontophoresis alone (Langkjear, 1994). Similar results were seen with leutenizing 
hormone releasing hormone (LHRH) using oleic acid as an enhancer along with 
iontophoresis (Bhatia, 1997). However, the most promising study seems to be the 
combination of iontophoresis with electroporation (Prausnitz, 1994). This will be 
discussed in the following section of electroporation. 
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1.5.3.2 Sonophoresis: 
Use of high frequency sound waves - ultrasound to deliver drugs and even 
macromolecules has been shown in several studies (Kost, 1993). The enhancement 
is influenced by the frequency used ( 20 kHz to 1 0 MHz) and the intensity (0-3.0 
W/cm2) with either pulsed exposure (1 :1 to 1:1 0) or continuous exposure ( <1 Omins). 
The biggest limitation is the local heating of tissue which can be reduced by 
decreasing the pulse exposure. Low frequency ultrasound has been shown to have 
better enhancement ratios (Mitragotri, 1995a). There are several proposed 
mechanisms to explain the enhancement oftransdermal drug delivery by ultrasound 
which include cavitation, thermal effects, generation of convective velocities, and 
mechanical effects. Cavitation or formation of air bubbles within skin, has been 
shown to occur in the keratinocytes of the SC upon ultrasound exposure. Cavitation 
has been attributed to the presence of a tensile cycle (negative pressure), which is 
always present in ultrasound (Miller, 1996). It is hypothesized that oscillations of the 
cavitation bubbles induce disorder in the SC lipid bilayers, thereby enhancing 
transdermal transport (Mitragotri, 1995b). However, the contribution to transdermal 
drug delivery enhancement due to heating and ultrasound has not been clearly 
established. 
Ultrasound has also been used for non-invasive monitoring of glucose and 
other biochemicals (Kost, 2000) similar to iontophoresis. Here vacuum is applied 
after ultrasound to extract interstitial fluid from the skin and analyze the various 
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biochemicals in this extract. Further, sonophoresis has also been combined with 
iontophoresis to deliver macromolecules like heparin (Le,2000). However, tissue 
damage may occur in sonophoresis (Byl, 1995) and is attributed to cavitation 
(Bommannan, 1992). 
1.5.3.3 Microfabricated microneedles: 
This is a very recent addition to transdermal drug delivery enhancers. This 
method utilizes micro-fabricated array of micron sized needles etched on silicon 
using ion etching procedure similar to the one used in manufacture of integrated 
circuits (Henry, 1998). These can be inserted into the skin thereby creating conduits 
within the SC. Once past the SC these compounds can easily diffuse into the dermis 
and be taken up by the capillaries. Increased flux upto 104 times compared to 
passive diffusion have been reported for calcein (Henry,1998). However, the device 
is in its infancy and its safety will have to be clearly proven, especially to show that 
the microneedles do not get broken or detached within the SC. 
1.5.3.4 Powderject™ system: 
High-velocity powder injection is a promising new drug-delivery technique that 
provides needle- and pain-free delivery alternative for proteins, peptides, and 
oligonucleotides as well as traditional and genetic vaccines (Burkoth, 1999). The 
energy of a transient helium gas jet accelerates fine drug particles of 20 microns-1 00 
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microns diameter to high velocities and delivers them into skin. This method was 
used to deliver antigens transdermally and has been shown to produce excellent 
immunizations (Tacket (1999), Degano(1998)). 
1.5.3.5 Photomechanical waves: 
Large molecules of upto 40 kDa of dextran molecules have been delivered 
using photomechanical waves (Lee, 1998a). These are produced by the ablation of 
a target material with a laser in a donor solution placed in contact with skin. The 
photomechanical waves produced due to ablation of the target get transmitted into 
the skin to produce changes in the skin, which cause the increase in permeability. 
Unlike ultrasound, photomechanical waves do not generate cavitation (Doukas, 
1995). In cells the photomechanical waves seem to act on the membrane integral 
proteins increasing trans-cellular permeation. Similarly it is hypothesized ·that 
photomechanical waves might act on the corneodesmosomes increasing the 
permeability of SC (Lee, 1999). However, the mechanism of this method in 
increasing transdermal drug permeation is not clearly understood. The main 
disadvantage of this system is that the target gets ablated and can potentially get 
permeated in the skin along with the drug. 
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1.5.4 Electroporation: 
Electroporation would also be classified as a physical enhancer. However, to 
provide easier readability and a detailed background for studies undertaken in this 
manuscript, it has been dealt with under a new heading. 
1.5.4.1 What and how ? 
Application of high voltages to cells transiently alters their membrane 
potential. This phenomenon has been used to transfect cells with macromolecules 
like DNA, proteins and oligoneucleotides (Weaver, 1995). These voltages are 
believed to cause pore formation within the lipid bilayer membranes, the exact cause 
of which has not yet been ascertained. Similar electrically induced pore formation · 
or electroporation has been observed in different bilayers seemingly independent 
of the composition. This prompted its first transdermal application in 1993 by 
Prausnitz et al with very promising results. The SC of the skin resembles the cellular 
membrane in that it has lipid bilayers, however, it is much more complex than a 
simple single bilayer lipid membrane. The SC has around 50-100 bilayers alternating 
with aqueous channels, and the presence of corneocytes further complicates the 
structure. Molecular rearrangement within the lipids forming aqueous channels is 
believed to be the cause of increased molecular transport across a cell membrane 
after electroporation (Weaver, 1993), similarly in the SC it is shown to be the 
formation of localized transport regions or L TR's (Piiquett, 1996d). Up to 104 times 
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increase in epidermal molecular flux has been noted with calcien due to 
electroporation compared to passive diffusion (Prausnitz, 1993a). 
1.5.4.2 Changes in properties of skin after electroporation 
Studies on various properties of the SC have been carried out, observing the 
effect of electroporation on these properties. Such studies help in understanding the 
mechanistic basis of electroporation. The first of such studies observed the changes 
in the passive electrical properties of the SC after electroporation (Piiquett, 1995). 
The presence of aqueous channels alternating with lipid bilayers gives the SC, 
properties of electrical resistance and impedance, where the resistance was 
attributed to the aqueous channels and the capacitance to the lipids in the bilayers. 
Essentially, an intact SC has been shown to have a very high resistance and 
impedance spectroscopy also revealed a capacitative component. After 
electroporation there was a dramatic drop in the resistance and an increase in the 
capacitative factor (Piiquett, 1995). The decrease in resistance rather than an 
increase in the capacitance correlated directly with increased calcein transport. This 
is because the transport of small ions through aqueous pathways will be indicative 
of pathways available for the transport of molecules that can "fit" into these 
pathways. In contrast, the pathways for ac current flow, i.e. involving voltage 
changes with higher frequency components, can involve displacement currents 
through capacitance elements. However, there is no actual transport of ions across 
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these capacitances. For this reason, the capacitance-based pathways do not 
contribute to ionic or molecular transport across the skin. These electrical changes 
were reversible within milliseconds to hours, depending on the various electrical 
parameters used. The reversibility was slower when pulse length or applied voltage 
was increased. This places a limit to the electrical parameters that can be used 
safely and effectively at least for chronic applications involving the same site. 
However, a combined study of passive electrical properties along with molecular flux 
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(A) Intact lipid bilayer- before electroporation 
(B) Hydrophobic pore (C) Hydrophilic pore 
after electroporation after electroporation 
Figure 1.4: Schematic of the changes in lipid bilayer occurring after 
electroporation. 
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studies can be useful to screen the reversible and effective electrical parameters 
which can be used for a particular molecular species. 
The order in which the lipid bilayers are arranged within the SC can be 
studied using X-ray scattering as well as differential thermal analysis (DTA). X-ray 
scattering studies showed an decrease of the small angle x-ray scattering (SAXS) 
peaks with no shift. The decrease was more pronounced with long pulses and low 
voltages indicating a disordering in the lipid lamellar packing as well as lipid lateral 
packing. Similarly, the intensity of wide angle x-ray scattering peaks (WAXS) was 
also decreased indicating a shift from crystalline phase to liquid phase. These 
changes were not significant with short pulses of high voltage and it has been 
suggested that such pulses could have caused localized changes which are 
undetectable by X-ray scattering (Jadoul, 1997). Similarly, the DTA studies show a 
decrease in the enthalpy indicating generalized disordering within the lipid bilayers 
rather than shift in the transition peaks of the SC which has been correlated to the 
increase in water content of SC (Jadoul, 1998). However, in this study the skin was 
hydrated initially for 2 hrs in both the control and electroporation treated samples, 
thus the shift in peak was either very small or insignificant Studies using FTIRIATR-
FTIR have shown that there is an increase in SC hydration after iontophoresis 
treatment (Jadoul, 1996 and Clancy, 1994). Both, X-ray diffraction and DTA 
concluded that generalized changes were occurring in the lipid ordering of the skin 
mainly because these methods were capable of only recording bulk phenomenon. 
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Pliquett et al, performed confocal fluorescence microscopy to observe the 
electro-transport of calcein and sulforhodamine in real time using electroporation 
(Piiquett, 1996d). The probes followed a localized transport pathway across the SC 
as seen from the regions of fluorescence which were interpreted in the study as 
"sites where transport had taken place". These regions did not coincide with 
appendages. In fact sulforhodamine did not show any fluorescence associated with 
appendages. The intensity of calcein fluorescence associated with appendages was 
comparatively much less than that associated with the L TR's. Interestingly, 
increasing the number of pulses beyond three, at a constant voltage, did not 
increase the number of L TR's. Also, fluorescence was found within the keratinocyte 
interiors which may suggest that transcellular transport has occurred (Prausnitz, 
1996c). 
Other visualization methods for example electron microscopy, freeze fracture 
electron microscopy (FFEM) have also been used to observe the microscopic 
morphological changes in the SC after electroporation. A host of ultrastructural 
changes have been observed including generalized disordering in the lamellar 
structure, formation of network like structures and spherical deformation, however, 
no changes in the protein fine structure were observed in the cross-sections 
indicating that the changes are manifested mainly in the lipid ordering and not the 
keratinous matrix of the corneocytes. 
Gallo et al, performed similar experiments with a modified freeze-fracture 
electron microscopy (FFEM) apparatus designed to reduce temporal resolution time 
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as well as to provide structural details which are beyond the scope of fluorescence 
imaging as performed earlier (Gallo, 1999). These images showed formation of 
vesicle aggregates which increased in density from 0.5 sec after the pulse to 5 sec 
after the pulse and thereafter decreased until 5 min after they completely 
disappeared. These aggregates seem to be similar to the L TR's. However, both of 
these phenomena do not directly correlate with the dramatic decrease in the 
resistance within microseconds of pulsing since the aggregate formation increased 
0.5 sec after pulsing. Nevertheless, they correlated reasonably with the recovery of 
resistance over minutes since the number of aggregates decreased after 5 sec until 
5 min whereby they were nearly absent The temporal resolution of the fluorescence 
study was 0.5 sec and hence it would not be possible to directly correlate whether 
the L TR's were the remains of the elusive electropores. Similar aggregates at a 
lower density formed after heating the SC to about 60°C. Intense hydration of SC 
also may lead to aggregate formation (Van Hal, 1996). However, studies on dry SC 
have not been performed yet, hence aggregate formation cannot be clearly related 
to hydration. 
1.5.4.3 Explanations and mechanistic analysis : 
All the above studies have to some extent helped in understanding the 
electrical behavior (voltage, conductance, and capacitance of skin), mechanical 
behavior (rupture or recovery of skin) and to some extent molecular transport after 
electroporation. Nevertheless, the primary phenomenon involving the molecular 
changes and the final recovery of barrier function still remains unexplained. 
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Many theories have been proposed to explain the changes that take place 
after electroporation, one of the reasons include changes due to joule heating 
occurring within local regions of skin. The SC is not completely homogeneous, 
although the bulk of the lipids shows a solid-crystalline nature with a transition 
temperature of around 65°C. The SC has some regions (-1 %) of fluidity due to lipids 
of lower transition temperature. Similarly, corneodesmosomes are also considered 
relatively permeable structures. The upper layers of the SC are relatively devoid of 
these structures, making them more permeable. These so called "defects" in the SC 
are considered as the preferred sites ofelectroporation (Piiquett, 1999). Electric field 
can force electrolyte into these regions leading to the initial fast (<10 IJS) decrease 
in the resistance and increase in current density within this regions. This might lead 
to joule heating and heating of the surrounding lipids and creating new aqueous 
pathways which result in a further decrease in the resistance and as long as the 
electric field lasts the heating front is propagated. Localized heating may even 
exceed the transition temperature of the lipids, causing a further drop in the 
resistance. Experimentally such regions have been observed using liquid crystals 
which respond to temperature by a color change (Piiquett, 2000d). The FFEM 
studies also point towards a similar mechanism, although indirectly, through 
observation of the secondary changes i.e. lateral diffusion of water within the SC 
leading to creation of new pathways, as inferred in the study (Gallo, 1999). 
Once these pathways are formed the molecular transport may occur due to 
either electrophoresis, electro-osmosis, or pressure/concentration gradients or a 
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combination of these phenomenon. The molecular transport after electroporation has 
been modeled to predict the functional dependence of transport molecules to various 
structural features of the SC (Chizmadzev, 1995). A straight-through pathway 
(transcellular) was shown to be more favorable compared to a tortuous pathway 
(intercellular). This is also consistent with recent studies which suggest that 
molecular transport is localized within the SC and is associated with the sites of 
electroporation. It follows a straight-through path along the bulk of the SC. This 
study was done with fluorescent probes, calcein and sulforhodamine, which were 
delivered into the skin by electroporation followed by low voltage iontophoresis. A 
gel was set immediately below the skin on the epidermal side to trap the probes 
coming out of the SC. Examination of the gel showed that the fluorescent probes 
were localized within the gels suggesting that they followed a localized pathway 
within the skin, termed as the L TR's (Piiquett, 1996d). 
Recovery of the resistance starts immediately on stopping the pulse and 
reaches 10 - 80% of prepulse value within 30 ms of stopping the pulse depending 
on the pulsing protocol. The regions where the transition temperature has exceeded 
may not recover or exhibit a very slow recovery, thus accounting for the incomplete 
recovery of resistance over minutes to hours or sometimes days (Piiquett, 1995b and 
1996e). 
Since the SC is not as homogeneous as single bilayers, the electroporation 
pathways differ in their location with the applied voltage. Primarily, low voltages (5-
50 V) have been shown to electroporate the appendages since these have lesser 
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lipid bilayers and hence the transmembrane voltage limit for electroporation can be 
easily reached in these regions. Several experiments have shown this phenomenon 
(Chizmadzev, 1998). However, as the voltage is increased (>50) electroporation of 
the bulk starts becoming more prominent (Piiquett, 1996e ). Theoretical fitting of 
molecular flux data (of Prausnitz, 1993a) by Chizmadzev has shown that the 
transcorneal pathway gives a better fit for the observed phenomenon compared to 
the intercellular or appendageal pathways. Similar conclusions were obtained by 
Edwards et al (1995) who used actual dimensions of the SC fine structures to 
calculate the best available pathways for electroporative molecular transport and 
compared them to the molecular flux obtained by Prausnitz et al (1993a). 
Electroporation had been likened to iontophoresis occurring at higher 
voltages. However, the idea has been successfully disproved. The molecular 
transport in iontophoresis utilizes the phenomenon of electrorepulsion, electro-
osmosis and to some extent passive diffusion, however, most of these take place 
through pre-existing pathways mainly, the appendages (Cullander, 1992b). In 
electroporation however, new aqueous pathways have shown to be created which 
are not associated with the appendages (Chen, 1998). In fact, the study showed that 
iontophoresis did not show any molecular transport in snake skin which has no hair 
or hair follicles, but electroporation did show significant transport (Chen, 1998). 
Prausnitz, has given sufficient evidence for the differences between iontophoresis 
and electroporation (Prausnitz, 1996d). 
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1.5.4.4 Electroporation candidates 
Many advantages of electroporation make it a versatile technique for the 
delivery of large variety of molecules. In vivo results with transdermal electroporation 
have shown that the drug delivery is fast, quite similar to an intravenous injection . 
(Vanbever, 1998a). Moreover, this technique is non.:.invasive unlike an intravenous 
injection. Several in vitro experiments have shown that complete control over the 
drug delivery is possible, with large amount of drug being delivered when required 
(Prausnitz, 1994). These flux increases have been shown to be reversible. 
Most importantly, electroporation does not place any restrictions on the 
physico-chemical properties or the molecules that can be delivered across the skin. 
Drugs with various physico-chemical properties have been delivered in vitro using 
electroporation. Prausnitz has reviewed the wide range of charged (positive or 
negative) and uncharged, small and large molecules, lipophilic or hydrophilic drugs. 
Results have been shown to produce appreciable transdermal flux enhancements 
by electroporation compared to passive or control samples (Prausnitz, 1999). 
Cyclosporine, a highly lipophilic drug, which has negligible transdermal delivery by 
passive diffusion, showed an insignificant enhancement of flux by electroporation 
alone. However, when the skin was pre-treated with a chemical enhancer like 
alcohol and then electroporated, the flux increased considerably (Wang, 1998). 
1.5.4.4.1 Chemotherapeutic agents 
By electroporation of tumor cells, the accessibility of an chemotherapeutic 
agent into the cell can be increased, thus increasing its efficiency. One of the first 
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studies was done using bleomycin and the success of the study triggered a wave of 
new studies using different chemotherapeutic agents, so much so that they have 
reached stage II and Ill of clinical trials, using electro chemotherapy (Heller, 1996). 
Combined with chemotherapy, electroporation has increased efficiency of 
anti-cancer agents in surface tumors dramatically (Mir 1991 and Belehradek, 1993). 
Electro chemotherapy is a new therapeutic alternative to treat surface tumors 
especially of head and neck since these are difficult to remove by other modalities 
like surgery and chemotherapy. Several other forms of tumors can also be treated 
by electro chemotherapy (Hoffmann, 1999 and Mir, 1999). 
1.5.4.4.2 Macromolecules - proteins, peptides, genes, oligonucleotides 
The technique has shown potential to deliver macromolecules like insulin, 
en kephalin and LHRH in significantly higher quantities compared to passive or even 
iontophoretic delivery (Potts, 1997). This shows the potential for transdermal 
delivery of proteins and peptides with electroporation (Banga, 1998b). Delivery of 
oligoneucleotides, plasmids and genes have been shown to be possible with 
electroporation in vitro and in vivo (Nishi, 1996, Zhang, 1996, Rols, 1998, Regnier, 
1997 and 1999). Some of these techniques involve delivery of the plasmids or genes 
by intra-atrial injections and then application of electroporation to increase ·local 
transfection rates. 
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An interesting phenomenon was observed with delivery of heparin with 
electroporation. The transdermal electroporative flux of smaller molecules was 
higher in the presence of a macromolecule like heparin and remained elevated long 
after the pulsing was stopped (Vanbever, 1997). It was found that only linear 
macromolecules produce this enhancement. This effect has been explained using 
a "foot-in-the-door" hypothesis, large molecules seem to prevent the resealing of the 
pores created during electroporation and thereby increasing the flux of smaller 
molecules (Weaver, 1997). Thus, this phenomenon has the potential to be used as 
an enhancer for transdermal electroporation, further increasing the flux of smaller 
molecules. 
1.5.4.5 Electroporation with other enhancers: 
1.5.4.5.1. With iontophoresis 
In vitro studies with LHRH and calcitonin have successfully shown that 
electroporation given before iontophoresis is more effective than iontophoresis alone 
(Riviere, 1995 and Bommannan, 1994). Since electroporation creates new 
pathways, application of iontophoresis after an electroporation pulse would provide 
more pathways for the current to travel and therefore. increase the molecular flux. 
Iontophoresis and electroporation can be combined to provide complete control over 
delivery, where iontophoresis can be used to maintain the basal level of a drug and 
electroporation used to deliver high drug doses when required. Such a system could 
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prove very useful for the delivery of molecules like insulin which require variable 
dosing, with high dose required after meals followed by basal levels between meals. 
1.5.4.5.2. With ultrasound 
A combination of electroporation and sonophoresis i.e. ultrasound application 
to skin produced a synergistic effect (Kost, 1996). This could be due to the fact that 
both produce alterations in the lipid structure of the SC. Such a combination would 
reduce the intensity of electrical pulses or ultrasound required to produce the same 
drug flux, thus decreasing the chances of any harmful effect. 
1.5.4.5.3. With keratinolytics and pressure 
Electroporation has been shown to deliver drugs across the SC through the 
formation of L TR's. llic et al(1999), have devised a system to restrict these L TR's to 
occur in microholes (40-100 !Jm diameters) of a thin electrically insulating sheet 
placed close to the skin. As an extension to this they delivered a low-toxicity 
keratinolytic molecule through the L TR's into the corneocytes to create 
microconduits in this restricted area. Thus, a combination of new aqueous pathways 
through the multi lamellar lipid bilayer membranes and subsequent disruption of the 
keratin matrix by the keratinolytic molecule is believed to result in dislodgement of 
entire stacks of corneocytes, creating -50-!Jm diameter microconduits through the 
SC. This provides unrestricted pathway for any water soluble molecule to the 
epidermis. Weaver et al, have delivered macromolecules as well as charged beads 
across the SC with this method with application of sl ight pressure. Ultimately, this 
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type of system has been proposed for delivery of macromolecules or even sampling 
of interstitial fluids. This type of system would mimic the traditional needle system 
eliminating the pain. However, the barrier property of skin would be compromised 
for a longer time than electroporation alone, since the recovery of skin following 
keratinolysis would be slow. Further studies are needed on the safety and 
consequences of long term application of this method. 
1.5.4.5.4 Electroincorporation 
Hoffmann et al, 1995 have devised a new type of electrode - The meander 
electrode- to restrict the electric field during electroporation only to the SC 
(Hoffmann, 1995). The design consists of closely spaced array of electrodes 0.2 mm 
thick with a gap of 0.2 mm between two electrodes. These electrodes can be placed 
on the skin and the electric pulses applied. The hypothesis is that since the gap 
between the electrodes is so small, the electric current has to travel a smaller 
distance within the skin, resulting in a swallow distribution of electric field. This could 
lead to electroporation of the SC only and since the current does not travel deeper 
into the epidermis and dermis it can prevent unwanted nerve stimulation. This 
translates into less sensations and less pain. In such a system, the electroporation 
would most likely occur at the sites of deformities leading to field enhancement or 
at structurally weak points such as existing channels. If particulates like liposomes 
are placed in the pathway of the electric field, there would be local field 
enhancements making the surface beneath them preferred sites for breakdown. 
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Initial pulses are believed to cause pore formation, with the following pulses causing 
pore enlargements. The enlargements are proportional to the follow through current 
and energy deposited into the pores which in turn is related to the resistivity offered 
by the media between the electrode and SC. The meander electrodes are directly 
placed on the skin without any conductive liquid between. This reduces the 
resistivity between the electrode and SC and thus a higher energy can be deposited 
into the pores formed within the SC after the first pulse. This can lead to larger pore 
diameters, making delivery of particulates possible. Hoffmann et al, have delivered 
solid latex particles with a diameter of 0.3-0.45 IJm across the SC by 
electroincorporation. Liposomes seem to elongate under the presence of electric 
field and such elongated liposomes were observed within the viable epidermis using 
the electroincoporation technique (Hoffmann, 1995). 
It has to be noted however that results of studies for sensation with the 
Meander electrodes gave a threshold of 80 V and 20 ms on the facial skin (Zhang, 
1999). Possibly the threshold on forearm could have been higher, but were not 
reported in the above study. The Meander type of electrodes have not been 
compared with conventional plate or wire electrodes. Further studies might be 
needed to confirm whether they have a better safety profile and comparable efficacy 
with regards to drug delivery. 
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1.5.4.6 Present challenges in electroporation (Statement of problem) 
Since the exact molecular basis for electroporation has not yet been 
identified, it is difficult to predict the molecular flux with any particular set of electrical 
conditions and for a given drug. There exist a large number of variables. The voltage 
to be applied can range from 100 V to 1000 V. Similarly, the pulse length can vary 
between several microseconds to milliseconds. The other variables include, number 
of pulses, rate of pulsing and electrode design. It is difficult to assess the delivery 
potential of these variables in combination, making the choice empirical. This puts 
safety in vivo at question. 
High voltage electric pulses are applied to the body in several clinical 
techniques such as, transcutaneous nerve stimulation, cardiac defibrillators, 
electroconvulsive therapy etc; these techniques present as precedents for use of 
electroporation in humans (Prausnitz, 1996b ). However, the safety of electroporation 
has to be assessed, mainly because of the large currents generated, unlike in the 
other methods. These currents have the potential to cause stimulation of nerves, 
pain and also tissue damage. Nerve stimulation beyond a certain limit will lead to 
pain, which itself can be the limiting cause for the use of electroporation in vivo. The 
voltage and pulse lengths (-100 IJS) used in electro chemotherapy clinical trials did 
not produce any pain in the patients. However, the in vitro transdermal drug delivery 
studies in the literature predict very minimal or no enhancement at the low pulse 
lengths used in these trials. It would be necessary to know whether patients can 
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tolerate higher pulse lengths, especially, since the patients in the above trials did 
experience involuntary muscle contraction at the low pulse lengths. If not then ways 
will have to be devised to make electroporation effective at low pulse lengths. One 
way would be to use synergetic enhancers. 
Although, some in vivo biophysical studies . with electroporation and 
iontophoresis have indicated no differences between the two with respect to the 
changes caused in the skin. The electrical pulses used in the study were chosen 
arbitrarily and the safety cannot be extrapolated to any other conditions. Neither 
were any biochemical changes in the skin studied. So far there is no biophysical or 
biochemical basis established for the cause of the changes if any. Such studies 
would be necessary to establish safety of electroporation during chronic use. Thus, 
only "proof of principle" studies exist on the safety and efficiency of electroporation. 
Many more studies are required before this technique can be utilized in vivo. 
1.5.4. 7 Previous work in our laboratory 
Initial focus of our laboratory was to evaluate electroporation for delivery of 
highly lipophilic drugs. Studies with cyclosporine showed that electroporation alone 
was ineffective in increasing the flux. But combined with a chemical enhancer like 
alcohol did produce acceptable results (Wang 1997 and 1998). As a means of using 
electroporation for delivering peptides we first planned to study the safety and 
efficacy of electroporation using a model drug which would be easier to analyze 
quantitatively and present less formulation restraints than peptides. This led us to 
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terazosin hydrochloride, a moderate sized drug with fluorescence, which could be 
beneficial to the analysis. Terazosin is not highly hydrophilic or lipophilic hence we 
could eliminate formulation problems as well as prevent complications in the delivery 
aspect. Systematic optimization of the electrical parameters for electroporative 
transdermal delivery of terazosin was carried out with efficacy and safety in mind 
(Sharma 1999). Preliminary investigations into the safety of electroporation were 
also performed using electron microscopy to observe any morphological changes. 
To further improve the efficacy of electroporation we devised novel electrode 
systems and carried out in vitro studies to prove their efficacy (Sharma,2000a, b). 
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2.0 Objectives and Research Plan 
2.10bjectives: 
The present research plan was developed in light of the work done previously 
in our laboratory and the problems faced in the area of transdermal drug delivery 
with electroporation. 
Specifically, we plan to carry out further optimization of electroporation 
parameters for the transdermal delivery of terazosin hydrochloride. Assess the 
potential of these optimized parameters to deliver the drug in vivo. Test our 
hypothesis that larger electrode area leads to better drug delivery by conducting in 
vivo studies with electrodes of different areas. Most importantly, assess the safety 
of these parameters in specific, and electroporation in general, through various in 
vitro and in vivo techniques. 
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2.2 Research Plan 
a. To optimize the following electrical parameters for transdermal delivery of 
terazosin hydrochloride by electroporation 
(i) Rate of pulsing 
(ii) Pulse length 
(iii) Concentration 
b. To characterize three electrodes of different areas (for delivering electroporative 
pulses to skin) with respect to the transdermal voltage produced, current density 
produced etc; 
c. To evaluate the above (in vitro optimized) electrical parameters for electroporative 
delivery of terazosin hydrochloride, in vivo, in fuzzy rats using a large area and small 
area electrode. 
d. To carry out studies to assess the safety of electroporation in vivo and in vitro, 
specifically: 
i) To observe the animal behavior and gross changes in skin occurring during and 
after electroporation pulses, 
ii) To estimate the electrical parameter which might best predict the safety/recovery 
after electroporation in vivo, 
iii) Conducting in vivo impedance measurements before and after various 
electroporation protocols and observe the recovery of impedance, and 
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iv) To observe the biochemical changes in skin occurring after electroporation, 
specifically to look for changes in the pattern of glucose utilization by skin before 
and after electroporation, thus establishing an in vitro method for assessing the 
safety of electroporation. 
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3.0 Materials and Methods : 
3.1 Chemicals : 
Terazosin hydrochloride (TRZ) [1-( 4-amino-6, 7 -dimethoxy-2-quinazolinyl)-4-
(2-tertrahydrofuroyl) piperazine hydrochloride dihydrate] was provided by Abbott 
Laboratories, QC, Canada (Mol. Wt. Of terazosin = 387.44). The internal standard 
for HPLC assay ofTRZ, prazosin hydrochloride (PRZ) [1-(4-amino-6, 7 -dimethoxy-2-
quinazolinyl)-4-(2-furoyl) piperazine hydrochloride monohydrate] was purchased 
from Sigma Chemicals Co., MO, USA For biochemical studies of skin after 
electroporation, lactate analysis kits (No.826 UV) were procured from Sigma 
Diagnostics, MO, USA and Eagle's Minimum Essential Media (MEM) with Earle's 
Balanced Salt Solution (BSS) was purchased from Sigma Chemical Co., MO, USA 
All other solvents and reagents used were of HPLC or analytical grade, respectively. 
Deionized water was obtained using a Barnstead® Nanopure II system (Barnstead, 
MA, USA). Cyanopropyl bonded silica Solid Phase Extraction (SPE) cartridges 
(Bond Elut®, 1 OOmg, 1 ml) were obtained from Varian Sample Preparation Products, 
CA, USA 
3.2 Choice of animals : 
Ideally, human skin would be best for conducting in vitro investigation of any 
transdermal phenomenon, however the difficulty of obtaining human skin requires 
that animal skin be used for preliminary studies such as this. It was reported that 
animal skin is generally more permeable than human skin (Bronaugh, 1982). The 
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choice of animal model in part may depend on the ease of preparation of skin for 
diffusion cells. Hairless animals such as fuzzy rat or hairless guinea pig provide 
satisfactory substitutes (Bronaugh,1991.and Marit,1995). Since hairless guinea pigs 
were not easily available fuzzy rats were used here. 
Seven to eight week old male fuzzy rats were procured from Harlan Sprague-
Dawley, IN, USA The rats were housed in the Animal Care Center, Memorial 
University of Newfoundland and cared in accordance with CCAC institutional 
guidelines. Plasma for calibration curves was obtained from eight to ten week old in-
bred male albino rats (Vivarium, Memorial University of Newfoundland, St.John's, 
Canada). 
3.3 Electroporation Unit and Electrodes : 
A Gene Pulse~ II (Bio-Rad Laboratories, Hercules, CA, USA) was used as 
the source for generating single and multiple exponentially decaying electrical 
pulses, with a pulse length of "-r" defined as, the time taken for the applied voltage 
(Uelectrode,o) to decay to 37% of its peak value. The shocking chamber of the 
electroporation unit was replaced with custom made silver/silver chloride electrode. 
The Gene Pulse~ II was equipped with a capacitance extender, a pulse controller 
unit and a panel that displayed the applied voltage (the actual voltage drop across 
the two electrodes), pulse length in milliseconds and internal resistance of system. 
The Uelectrode 0 can be defined as the peak value of voltage of an exponentially 
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decaying electric field applied between anode and cathode during pulsing. Custom 
made Ag/AgCI delivery electrodes consisted of silver wires (0.5 mm diameter) 
electro-coated with AgCI. The electrodes were either straight pieces of wire (small-
area electrode, 1X::: 0.2061 cm2) or spiraled loops of wire (large-area electrode, 5X 
::: 1. 023 cm2 and 15X ::: 3. 065 cm2). Studies of in vivo or in vitro electroporation in the 
literature (Vanbever, 1998 and 1999) have reported applied voltages. (Uerectrode 0 ) as 
opposed to transdermal voltages (Uskin,o>· Hence, to facilitate comparison we have 
reported applied voltages. 
3.4 Isolation of skin for in vitro drug delivery studies : 
The rats were sacrificed using a carbon dioxide chamber. Full thickness 
abdominal and back skin were excised and used within 8 hours. Sharma, 1999 has 
shown that, the location from where the skin is removed does not matter if the drug 
is estimated in the skin rather than the receiver compartment. Subcutaneous fat and 
muscle layers were carefully removed from the skin. The excised skin samples were 
hydrated by soaking for two hours in PBS (Phosphate Buffered Saline, pH 6.4, 0.1 
M). Skin samples below 2 KO were discarded since this could be the result of 
damaged /leaky skin. 
It is important to note that freshly excised skin was used as opposed to frozen 
skin since it has been shown that frozen skin loses its viability (Wester et al, 1998). 
Also, full thickness skin as opposed to separated epidermis was used here since 
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it has been shown that procedures used for separation of epidermis from dermis can 
damage skin viability (Wester et al, 1998). We believe that using full thickness skin 
would mimic in vivo conditions more closely than would using epidermis only. 
3.5 Choice of Drug- Terazosin Hydrochloride: 
Since the present work was a continuation of the previous study in our 
laboratory, the same drug used previously i.e. TRZ was used. Briefly, the drug was 
chosen for the ease with which it could be analyzed in skin by extraction and 
quantification by HPLC equipped with fluorescence detector. Since the drug allowed 
the use of fluorescence detection, the interference with skin lipids and enzymes 
during analysis can be reduced. 
3.6 In vitro Drug Delivery Optimization Experiments: 
3.6.1. Assembly in vitro drug delivery optimization experiments: 
Custom designed side-by side diffusion cells made of Delrin (Polymethanal, 
Dupont®) were used for all in vitro electroporation experiments. A freshly excised, 
full-thickness, fuzzy rat skin was sandwiched between the donor and receiver 
compartments, with the SC side of the skin facing the donor compartment. Multiple 
exponential pulses were delivered to the skin by placing the anode in the donor 
compartment which also contained TRZ solution (1.03 mg/rnL unless stated 
otherwise) in phosphate buffered saline {PBS, 0.1 M NaCI, 0.02 M phosphate, pH 
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6.4 ). The receiver chamber was used as the cathode chamber and contained only 
PBS. The effective diffusional cross-section area was 1.3 cm2. The electrodes were 
placed 10 mm from the skin in each compartment, with the anode on the donor side 
(Fig 3.1 ). All experiments were performed at room temperature (22 ± 1 OC). 
h-
Electroporator ~ h 
~+ 
Cath ode 
Anode (der mal side) 
(Stratum Skin 
Corneum side) 
Figure 3.1 : Assembly for in vitro drug delivery optimization. 
3.6.2 Drug delivery optimization experiments : 
In continuation of our previous experiments to optimize transdermal delivery 
of TRZ by electroporation (Sharma,2000a) we evaluated the effects of pulse length 
and rate of pulsing. Three pulse lengths were evaluated viz: 400V, 1 ppm, 10 pulses 
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were delivered with either one of 20 ms, 30 ms or 40 ms. Likewise three rates of 
pulsing were evaluated viz: 400 V, 20 ms, 10 pulses delivered at 1 pulse per min 
(ppm), 4 ppm or 10 ppm. The experiment was divided into two parts for studying 
each parameter : 
(i) The drug was kept in contact with the skin during pulsing and after pulsing for a 
total of 20 min. The control for this study was 20 min drug contact time but no 
electrical pulse applied (passive drug delivery). After the 20 min contact time, the 
skin was analyzed (ref 3.6.4) for TRZ content. The TRZ delivered under both 
conditions was compared to obtain the permeation enhancement by electroporation 
over passive delivery. 
(ii) During pulsing the donor side contained only PBS with no drug in it. Within 1 0 
seconds after pulsing the PBS was replaced with the drug solution and kept in 
contact for 1 0 min. The control for this study was 10 min drug contact time and no 
electrical pulse was applied (passive drug delivery). In either case after the 10 min 
contact time, the skin was analyzed (ref 3.6.4) for TRZ content. The amount of TRZ 
delivered was compared. If electroporation conditions cause complete reversibility 
then the permeability of skin should be the same as control (passive) and if drug was 
placed immediately after electroporation, the amount of drug in skin should be same 
as control (passive). Thus, this part of the experiment would tell us about the extent 
of skin recovery after the use of particular electroporation parameter(s). 
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The effect of donor concentration was also studied. 400 V, 20 ms, 10 pulses 
at 1 ppm were delivered with either 0.1 or 1 % TRZ solution in contact with skin for 
a total of 20 min (10 min during pulsing and 10 min after pulsing). Control for this 
was a 20 min passive drug delivery with either 0.1 or 1 % TRZ solution in contact 
with skin. After the 20 min contact time, the skin was analyzed (ref 3.6.4) for TRZ 
content. The delivery with and without electroporation was compared. 
3.6.3 In vitro experiments to characterize drug distribution in skin : 
Previous experiments in our laboratory had revealed different current density 
values across the skin for different size/shape electrodes (Sharma,2000b). We 
wanted to investigate whether this current density was uneven causing uneven (or 
localized) electroporation in · the skin and thus uneven drug distribution. An 
experiment was designed to characterize the · drug distribution in the skin after 
electroporation 
Electroporation pulses were delivered to skin with either a small area 
electrode (1X, 0.2061cm2) or a large area electrode((15X), 3.065cm2)] at Uelectrodeo of 
400 V, pulse length 20 ms, 10 pulses at 1 ppm with TRZ (1.0 mg/mL) in contact for 
20 min (1 0 min during pulsing and 10 min after pulsing). Control for this was a 20 
min passive drug delivery with TRZ (1.0 mg/mL) in contact with skin. After the 20 min 
contact period, the skiri was washed thrice with deionized water, stripped in a 
controlled manner with Scotch® tape thrice to remove the superficially adsorbed drug 
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(see Sec 3.6.4). Approximately 1.3 cm2 of the skin corresponding to the area 
exposed to the drug was cut and the excess area unexposed to the drug discarded. 
The exposed skin piece was further cut into three equal pieces, dried with Kim® 
wipes and weighed (Figure 3.2). One milliliter of methanol and an appropriate 
amount of PRZ was added to these pieces and then extracted as described in Sec 
3.6.4 and analyzed for TRZ content. The amount of TRZ in each skin piece was 
normalized to the weight of the piece. 
1 2 3 
Skin piece 
Figure 3. 2: Diagramatic representation of the way skin was cut for 
characterization of drug distribution. 
3.6.4 Extraction of drug from skin- sample preparation for HPLC: 
After pulsing, the diffusion chambers were emptied, dismantled and skin 
specimens were removed. The SC side of the skin was washed with deionized water 
three times and Scotch® adhesive tape (3M, Ontario, Canada) was used to strip it 
three times to remove any superficially attached drug. It was found that the drug in 
the tape strips was less than 0.01% (Sharma, 1999). A biopsy punch was used to 
cut out 0.87 cm2 of the skin sample to quantify the TRZ delivered in the skin. This 
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sample was stored in 1 mL of methanol. An appropriate amount of PRZ was added 
to the solution, and the skin sample was homogenized using a Brinkmann 
homogenizer (Polytron, Switzerland). It was further extracted using 3 x 1 ml of 
methanol and centrifuged. The combined extracts were centrifuged and analyzed 
using HPLC for TRZ content (section 3.8). 
3. 7 In vivo Drug Delivery Experiments : 
3.7.1 Assembly for in vivo drug delivery experiments: 
Side ports 
(5 mm) 
Main port 
(Bmm) 
Nylon mesh 
Rubber 
o-nng 
Figure 3.3 : Diffusion cell for in vivo drug delivery experiment. 
A side-by-side diffusion cell unit, made of Plexiglass® (Acrylic, Johnson's 
Industrial Plastics Ltd, ON, Canada) was used. The rats were subjected to light 
halothane anaesthesia and then restrained using a cloth restrainer. The diffusion 
cells were then pinched together on a skin fold on the dorsal side the rat. The drug 
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solution (TRZ, 10.03 mglmL) in PBS was added to both cells to permit maximum 
delivery. The distance between the skin and electrodes during pulsing was 8 mm. 
A nylon mesh was placed between the skin and the electrode to prevent the 
electrodes from coming into direct contact with the skin (Figures 3.3 and 3.4). 
3.7.2/n vivo Drug Delivery Experiments: 
The drug delivery experiments were performed using the small area electrode 
with uelectrode,O of 400 v (Uskin,O ~ 100 V) and large area electrode with uelectrode,O of 250 
(Uskin 0 ~ 100 V) and 400 V (Uskin 0 ~ 160 V). This allowed comparison of the two 
' ' 
electrodes at similar values of both uelectrode,O and uskin,O. The other electrical 
parameters were taken from the optimization studies, viz: 20 ms pulse length, 20 
pulses at 10 pulses per minute (ppm). The electric pulses were applied and the rat 
was transferred back to its cage soon after the pulsing was over, the total drug 
contact time was 2 min. The controls consisted of passive drug delivery for either 
2 min or 20 min, with the same conditions as above but no electric pulses were 
applied. Intravenous drug (30 IJg I kg) was administered through the femoral vein. 
Subcutaneous injections (60 IJg I kg) were given on the abdominal side. The blood 
samples were taken from the sino-orbital vein of the rat maintained under halothane 
anaesthesia. These were immediately centrifuged at 13,000 g for 6 min and the 
isolated plasma samples were stored at -20°C until analysis. 
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Figure 3.4: Photograph of the assembly for in vivo drug delivery with 
electroporation. 
3.7.3 Extraction of drug from plasma by Solid Phase Extraction (SPE)- sample 
preparation for HPLC (Singh, 1995) : 
Bond Elut® columns for SPE were first conditioned using 1.0 ml of methanol 
followed by 1.0 ml of PBS (pH 7.0). Plasma samples (0.2 ml) were spiked with 
20~L of PRZ internal standard and 0.5 ml of phosphate buffer (pH 7.0), and mixed 
using a vortex mixer. The samples were then extracted using conditioned SPE 
columns with two 0.5ml portions of extraction solution consisting oftetrahydrofuran 
and acetonitrile in respective volume ratio of 1 :3. The eluate was evaporated to 
dryness using nitrogen gas in a thermostated water bath (37°C). The residue was 
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reconstitued in 1 OOtJL of mobile phase for HPLC analysis (section 3.8). For 
calibration curve determination the blank plasma was spiked with internal standard, 
PRZ, and standard solutions of TRZ and extracted similarly. 
3.8 Drug Analysis by HPLC (Singh, 1995): 
The HPLC system consisted of a Waters® Model 510 pump (Waters 
Associates, MA, USA), a Shimadzu® SIL-9A autoinjector and RF-535 Fluorescence 
HPLC monitor (Shimadzu Corporation, Kyoto, Japan). The fluorescence detector 
was set at an excitation wavelength of 345 nm and an emission wavelength of 400 
nm. The analytical column was a Waters® RCM 8 x 10 em cartridge packed with 
Nova-Pak® C18 reverse phase particles, fitted with Nova-Pak® C18 guard column. 
Responses were recorded as peaks on a LKB 2210® (Bromma, Sweden) recorder 
operated at the speed of 10 mm/min. The mobile phase consisted of phosphate 
buffer (pH 7.0), acetonitrile and tetrahydrofuran in the respective volume ratio of 
76:18:6. The mobile phase was clarified and degassed by filtering through a 0.221-Jm 
membrane filter at least twice (Millipore Corporation, MA, USA) and was pumped 
isocratically at a flow rate of 1.0 mUmin. Accumet® model pH meter (Fisher 
Scientific, PA, USA) was used to measure pH of the solutions. The in vivo sample 
extracts were quantified using the same HPLC procedure. 
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3.9 Measurements of Skin Electrical Parameters In Vitro: 
3.9.1 Assembly for measurements of skin electrical parameters in vitro: 
A side-by-side diffusion cell made with Plexiglass® (Acrylic, Johnson's Industrial 
Plastics Ltd, ON, Canada) was used. The cross-section area was maintained at 
1.3 cm2. Three holes were made on the donor and receiver side of the cell at 5, 
10 and 15 mm from the side to facilitate the insertion of electrodes. Two Ag/AgCI 
electrodes were placed in the nearest holes (inner electrodes) on either side (5 
mm) of the cell, these electrodes were simple pieces of silver wires (d = 0.5mm) 
electrocoated with silver chloride. Two Ag/AgCI electrodes were placed at 10 mm 
(outer electrodes) and these were either simple pieces of silver wires or spiraled 
silver wires (to increase electrode area, ref section 5.3) electrocoated with silver 
chloride. The inner electrodes were connected to channel 2 of a Tectronix 
oscilloscope through a 1:1 00 differential amplifier, whereas the outer electrodes 
were connected to the electroporator. A 5 ohm resistance was connected on the 
outer circuit in series with the diffusion cell (Figure 3.5) to measure the current 
flowing through the circuit. The voltage drop across the resistor was measured 
on channel 1 of the oscilloscope and the current was calculated using Ohms ~aw 
(I= V/R). The probes used to connect the amplifier were properly compensated 
and calibrated using a Eppley standard cell, The Eppley laboratory Inc., 
Newport,RI, USA. Freshly excised skin pieces were sandwiched between the 
diffusion cells. A fresh piece of skin was used for each pulse and all the 
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Figure 3. 5: Assembly for in vitro measurement of skin electrical parameters. 
parameters recorded and then discarded. PBS (pH 6.4) was used as the electrolyte . . 
3.9.2 Experimental procedures: 
Solution resistance (R501) was first calculated by applying a range of voltages 
( 1 00 to 1 000 V) using the outer electrodes (repeated for all different electrode areas) 
and measuring the voltage drop across the inner electrodes (Uinner 0) and current 
flowing through the circuit. 
..... (Eqn 3.1) 
To calculate the voltage drop across the skin (transdermal voltage, Uskin o), 
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various combination of Uelectrode,o and pulse lengths were applied to the skin using 
all three electrode sizes I types. The Uinner,o and 10 during each of these pulses were 
recorded. From these measurements the Uskin,o was calculated using the following 
equation: 
Uskin,o = Uinner,o - (Rsol X lo) ... .. (Eqn 3.2) 
Knowing the current in the circuit, pulse length and the transdermal voltage, 
a large number of parameters can be calculated (Sharma et al, 2000b) viz: dynamic 
resistance (Rdy) which is the resistance of the skin at the beginning (time = 0) of 
pulse, current density (current per unit area of skin), instantaneous power density 
to skin (Instantaneous power per unit area of skin), and energy density per pulse 
to the skin (energy per unit area of skin). The charge delivered to the skin (Q) can 
also be calculated. Since the current decreases exponentially it can be calculated 
as follows: 
.... (Eqn 3.3) 
3.1 0 In vivo Impedance Measurements : 
3.1 0.1 Assembly for in vivo impedance measurements : 
The assembly was similar to the one described above for in vivo drug delivery 
except that each of the cells had an additional hole at 5 mm from the open end to 
facilitate insertion of another pair of electrodes. The outer electrodes (at 8 mm from 
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Figure 3.6: Assembly for in vivo skin impedance measurements after 
electroporation. 
skin) used to deliver the electrical pulses were also connected to the impedance 
measurement equipment. The anode side was used as the working electrode and 
the cathode as the secondary electrode. The inner electrodes were connected to the 
spectrum analyzer (reference electrode1 to cathode side and reference electrode 
2 to the anode side). All the electrodes were connected using a switching unit. When 
the switch was turned on, it connected only the outer electrodes to the electroporator 
and the inner electrodes were disconnected and the assembly was ready for delivery 
of electroporation pulses. When the switch was in the off position, the outer and 
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inner electrodes were connected only to the impedance measurement equipment. 
The impedance data were recorded and analyzed using a computer software - Z-
plot© (Solartron analytical, TX, USA) (Fig 3.6). 
3.10.2. Experimental procedures for in vivo impedance measurements:· 
The animals were anaesthetized by giving sodium pentobarbitone by i.p. (50 
mg/kg) and restrained with cloth for the first two hours and released into their cages. 
Thereafter, they were restrained again only during each measurement. The diffusion 
cells were pinched on to the dorsal skin fold of the rats. The electrodes were 
arranged as described earlier (section 3.7.1 ). The real (representing the resistive 
component) and imaginary (representing the capacitive component) impedance (see 
sec 1.3.5.) was measured between 1 - 65,000 Hz with 0.0 bias. The data were 
captured in a software- Z plot© and a Nyquist plot was drawn using Sigma Plot© 5.0. 
This represented the passive impedance or control. The switch was then put "on" 
and electroporation pulses were delivered. The following protocols were evaluated 
(n=2 for each) : 
(i) 400 V, 1 ms, 1 pulse with 1 X electrode 
(ii) 400 V 10 ms, 1 pulse with 1X electrode 
(iii) 400 V, 20 ms, 20 pulses at 10 ppm with 1X electrode 
(iv) 400 V, 20 ms, 1 pulse with 15X electrode 
Immediately after pulsing (within 10 sec) the switch was put to the "off' position and 
the impedance measurement was started (0 hr). The impedance was recorded at 30 
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min, 1.0, 1.5, 2.5, 4.5, 7.5 and 24 hr after pulsing. The rats were put back into their 
cages after 2.5 hrs (or earlier if the anaesthesia wore off) and re-restrained during 
measurements only. The area of skin where cells had been attached was clearly 
marked with ink to help replace the cells again in the same spot. 
3.11 Skin Viability Assessment Using Glucose Utilization Index : 
3.11.1 Assembly for skin viability assessment and experimental procedure : 
Side-by-side diffusion cells with water jackets to maintain temperature at 37° C 
were used. The water temperature was maintained using thermostat by circulating 
it through a water bath. Each cell was equipped with a port for removing samples. 
Also, the contents of the cell were constantly stirred by using a magnetic bar and 
magnetic stirrer (Fig 3.7). The Minimum Essential Media with Earle's Balanced Salt 
Solution (MEM-BSS) was kept only on the receiver side and the dermal side, the SC 
side was kept empty. 
Freshly excised skin either (immediately) after electroporation treatment or 
without treatment was sandwiched between the two diffusion cells. The following 
treatments were carried out: 
(i) Passive- no electroporation pulses applied (n = 4) 
(ii) 400 V, 20 ms, 10 pulses at 1 ppm (n = 6) 
(iii) 500 V, 60 ms, 20 pulses at 1 ppm (n = 3) 
(iv) 1000 V, 5. 7 4 ms, 20 pulses at 1 ppm (n = 5) 
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Figure 3.7: Assembly for in vitro skin viability assessment. 
The electroporation pulses were delivered using the same assembly 
described in section 5.6.1, with PBS on both side of the skin. Immediately after 
pulsing (within 1 min) the skin was transferred to the assembly of Figure 6 and 
incubated with the medium. Samples of 100 IJL were withdrawn at 0 min, 2, 4, 6, 8, 
12 and 24 hr and replaced with 100 IJL of fresh media. The samples were analyzed 
immediately as described bel.ow. 
3.11.2 Background for lactate analysis : 
The ability of skin to convert glucose to lactate was used as a measure of the 
skin's viability (Wester, 1998), since this conversion involves the formation of 
adenosine triphosphate (ATP), which is the energy source of the living cells. 
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Glucose is one of the components of MEM-BSS media. Viable skin converts 
this to lactate, which is measured in this experiment. Sigma Diagnostic's, lactate 
analysis kit #826 UV was used. The procedure for the calibration curve and 
estimation of lactate was followed exactly as mentioned in the kit. The brief principle 
of the assay is described below: 
LD 
Pyruvate+ NADH <------->Lactate+ NAD 
Excess of nicotinamide adenine dinucleotide (NAD) is added to the lactate 
present in the solution in the presence of lactate dehydrogenase (LD). The pyruvate 
formed is trapped with hydrazine to force the ·above reaction to the left. The 
nicotinamide adenine dinucleotide dehydrogenate (NADH) formed is measured by 
UV spectrophotometry at A= 340 nm. 
3.11.3 Procedure for lactate analysis : 
Calibration curve :The lactate standard provided in the kit was diluted with water and 
then mixed with the analysis reagent (see below) to prepare the following lactate 
standards: 0, 12,36,60,96,120 mg/dl. The mixed solutions were incubated for 30 min 
at room temperature and then the UV absorbance at 340 nm was measured for each 
of the solutions. The concentration of lactate was plotted versus the absorbance 
and the regression equation was determined. 
Analysis: 100 !Jl ofthe test solution was incubated with 2.9 ml of reagent mixture 
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for 30 min at room temperature and the UV absorbance measured at 340 nm. The 
concentration in the test solution was calculated using the regression equation of the 
standards. 
The analysis reagent mixture contained glycine buffer (0.6 moi/L) and 
hydrazine, pH 9.2, NAD, lactate dehydrogenase, and distilled water. 
3.12 Data Analysis : 
All experiments were performed a minimum of three times and statistical 
calculations were done using Sigma Stat® 2.0 software. Group d~ta were compared 
using one way ANOVA followed by pairwise multiple comparison procedures 
(Tuckey test). 
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4.0 Results and Discussion: 
4.1 In vitro Electroporative Drug Delivery Studies : 
4.1.1 Drug delivery optimization : 
The difference between the amount of TRZ delivered to the skin when TRZ 
solution was brought in contact with the skin soon after delivering an electroporation 
pulse and the passive diffusion gives an idea of the degree of reversal of the skin's 
permeability. A drug delivery higher than passive diffusion indicates that the barrier 
property of skin has not completely recovered. Previously, Sharma et al used the 
reversibility of skin's permeability barrier as an index to evaluate safety of 
electroporation (Sharma, 2000b). Here the concept of reversibility was used to 
optimize the electrical parameters for drug delivery by electroporation. Possibly 
reversibility of the permeability barrier could have totally different mechanisms 
under in vitro and in vivo conditions. However, the long term safety of electroporation 
would require that the changes in skin permeability caused by electroporation be 
reversed as soon as possible. If not, the electroporation technique may be 
considered as invasive as an injection, defeating the original purpose of developing 
electroporation as a non-invasive delivery system. 
A) Effect of pulse length : Twenty pulses of 20 ms at Uelectrode 0 of 400V, were found 
optimal for TRZ delivery (Sharma, 2000a). The optimization was based on the 
efficiency of drug delivery and observation of gross changes in the skin. In our study 
three pulse lengths were investigated using reversibility of the barrier property. 
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Figure 4.1 shows the results of TRZ delivery obtained with ten pulses, 1 ppm and 
of 20, 30 or 40 ms at Uelectrooe 0 of 400 V. Amount of drug delivered increased with 
increase in pulse length. Figure 4.2 compares the passive delivery of TRZ 
obtained without subjecting the skin to any electroporation pulse with those obtained 
after subjecting the skin to 20, 30 and 40 ms lengths of electroporation pulses, and 
then introducing the drug to the already pulsed skin as stated above. The higher 
TRZ amount with the post-pulse passive diffusion indicates that the permeability of 
skin was irreversibly · increased. . Increasing pulse length from 20 ms to 30 ms 
caused a significant increase (p<O.OOS) in delivery. However, there was no 
significant difference between the TRZ levels obtained .after subjecting the skin to 
30 and 40 ms pulses. Decreasing pulse length below 20 ms to 1 0 ms, greatly . 
decreased the delivery of TRZ (Sharma, 2000a). Thus, to minimize any damage to 
the skin and obtain reasonable drug delivery 20 ms was chosen as the optimum 
pulse length at Uelectrooeo 400 V to deliver TRZ. 
B) Effect of rate of pulsing: The effect of three rates of pulsing was investigated, 
1 pulse per minute (ppm), 4 ppm and 10 ppm USing Uelectrode,O 400 V and 10 ms 
pulses. No differences were found (Figure 4.3) in the amount of TRZ delivered 
between the three pulse rates, 1 ppm, 4 ppm and 10 ppm (p>O.OS). Neither was 
there any difference between the reversibility profiles when the three pulse rates 
were compared (p>O.OS). 
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Figure 4.1 : Effect of increasing pulse length (x-axis) on TRZ delivery to skin (y-axis) 
-drug in contact with skin during and after electroporation. 
Other conditions were applied voltage of 400V, 1 0 pulses, 1 ppm with 1% TRZ in con-
tact with skin during and after pulsing for a total of 20 minutes. Passive was 20 minutes 
drug in contact with skin without pulsing. 
The electroporated samples are significantly different from passive diffusion (P<0.001) 
*The three electroporated samples are significantly different from each other (P<0.001). 
Statistical test was one-way ANOVA followed by pairwise multiple comparison 
procedures (Tuckey test). 
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Figure 4.2 : Effect of pulse length (x-axis) on amount TRZ delivered to the skin 
(y-axis)- Drug in contact with skin only after electroporation pulses were stopped. 
Other conditions were: applied voltage of 400V, 10 pulses, at 1 ppm with 1% TRZ 
placed in contact with skin, within 10 sec of stopping pulses, for a total of 10 min. 
and passive was 10 min without pulsing. 
Passive samples are significantly different from electroporated samples (P<0.001 ), 
The 20 ms samples are significantly different from 30 ms & 40 ms (P<0.005), 
The 30 ms and 40 ms samples were not significantly different from each other 
(P=0.75). Statistical test was one-way ANOVA followed by pairwise multiple com-
parison procedures (Tuckey test) 
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Figure 4.3: Effect of rate of pulsing (x-axis) on amount of TRZ delivered to 
the skin (y-axis). Other pulse conditions were; applied voltage of 400V, 20 ms, 
10 pulses, with 1% TRZ in contact with skin during and after pulsing, for a 
total of 20 minutes. Passive diffusion was 20 min drug delivery in contact with 
skin without pulsing. · 
There is. a significant difference between passive and electroporated samples 
(P<0.001). There is no significant difference between the three electroporation 
protocols (P = 0.27) Statistical test was one-way ANOVA followed by pairwise 
multiple comparison procedures (Tuckey test). 
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Figure 4.4: Effect of increasing donor TRZ concentration (x-axis) on amount 
of drug delivered to skin (y-axis) by electroporation and passive delivery. 
Pulsing conditions were 400V,20 ms, 10 pulses at 1ppm with1% or 10% w/v 
TRZ in contact with skin during and after pulsing for a total of 20 mins. Passive 
drug delivery consisted of 20 mins drug contact time with no pulses applied. 
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Earlier studies have pointed out that most of the drug was delivered during 
pulsing rather than after pulsing (Sharma, 2000b and Vanbever, 1996b). Thus, the 
drug could be kept in contact during pulsing only and removed soon after pulsing. 
Using a faster rate of pulsing would be beneficial in the in vivo studies, as the 
animals would have to be restrained for a shorter period of time and a larger number 
of pulses could be delivered in a relatively short period of time. 
C) Effect of drug concentration in the donor : Increasing the drug concentration 
from 1% to 1 0% resulted in increased TRZ delivery both during passive and 
electroporative treatments (Figure 4.4). The amount of TRZ delivered with the use 
of electroporation pulse increased from 21 j.Jg with 1% solution to 119 j.Jg with 10% 
solution. The nearly six fold increase in drug delivery may not be surprising. 
Nevertheless, maximizing drug concentration at the donor cell is an important aspect 
that could be utilized to minimize the use of electroporation pulses. Less number of 
pulses in a short time would improve compliance. 
To summarize, use of 20 pulses at 10 ppm with an Uelectrodeo of 400V and a 
pulse length of 20 ms were found to be optimal electroporation conditions for TRZ 
delivery. These electroporation conditions and the use of electrodes with varying 
surface areas were subsequently evaluated in vivo in rats. 
4.1.2 Characterization of drug distribution in skin : 
Sharma et al indicated possible non-uniformity in current density distribution 
with different shape/sized electrodes (Sharma, 2000b ). A small area electrode which 
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was basically a simple piece of wire produced a distinct red lesion on the skin after 
electroporation, parallel to the electrode. However, a large area electrode shaped 
as a spiraled coil did not produce any such deleterious effects at the same electrical 
conditions. This phenomenon was further investigated in the following study. The 
hypothesis was that if the electrode produces non-uniform current density, it would 
cause non-uniform electroporation within the skin and thus the drug diffusion would 
be non-uniform. 
In the study, the drug was delivered by electroporation with the above two 
types of electrodes after which the skin was cut into three equal pieces. Since the 
wire electrode produced a lesion parallel to its position, the skin was cut into three 
pieces of which the middle piece (subscript 2) was parallel to the wire electrode 
(Figure 3.2). For the large area electrode and control (passive delivery) the skin 
was cut in the same manner. The drug delivery was estimated in these pieces and . . 
the results were compared using one way ANOVA followed by multiple pairwise 
comparisons (Tuckey test). No differences in amount delivered were found between 
the three pieces for any electrodes (Table 4.1 ). It could be argued that lateral 
diffusion took place leading to uniform drug distribution within the skin. However, 
Pliquett, 1996d, and Chen, 1998a, have shown that the drug transport during 
electroporation occurs primarily through localized transport regions (L TR's) and that 
increasing the number of pulses only causes the L TR's to widen. Thus, an uneven 
current density during electroporation could have produced an uneven distribution 
74 
of L TR's and thus uneven drug distribution. However, this was not the case in this 
study. 
If an electrode is touching the skin or is very close to the skin, a burn may be 
produced (Hoffmann, 1999 and Pliquett, 1999). This could have been a cause of the 
lesion seen with the wire electrode in the previous study (Sharma 1999). Such 
contact can be prevented by using a wire mesh to separate the electrode from skin 
and also using a conductive gel to localize the electrode rather than an electrolyte 
solution. 
Table 4.1: Results of drug distribution experiment. P = Passive delivery (control), 
S =Small area electrode (wire electrode) L= Large area electrode (coiled 
electrode). Subscripts 1, 2 and 3 represent the three pieces cut out. n= 3-5 for all 
conditions, results are mean ± standard deviations. 
Condition Amount of TRZ in 
skin± SO 
(mg/g of skin) 
p1 0.018 ± 0.005 
p2 0.020 ± 0.008 
p~ 0.031 ± 0.02 
51 0.099 ± 0.014 
s2 0.146 ± 0.069 
s~ 0.13 ± 0.05 
L1 0.184 ± 0.024 
L2 0.176 ± 0.042 
L~ 0.157 ± 0.048 
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4.2 In Vivo Electroporation Studies : 
4.2.1 Safety of electroporation in vivo : 
The rats tolerated the electroporation pulses at Uelectrode 0of 400 V (Uskin 0 ~ 100 . .
V), although muscle twitching was seen during the pulse delivery. Electroporative 
delivery caused a slight discoloration of the rat skin at the site of delivery with the 
small-area electrode, Which subsided within a few minutes after stopping the pulse. 
This effect was not distinguishable from the discoloration produced by just pinching 
the diffusion cells to the rat skin. Electroporation pulses with the large area electrode 
at uelectrode,O of 250 v (Uskin,O ~ 100 V) also did not produce any visible damage. 
However, with the large area electrode at Uelectrodeo of 400 V (Uskin 0 ~ 150 V) . .
erythema, more pronounced on the anode side, developed within an hour of the 
treatment, and lasted for nearly a day. Edema, which lasted for a day, also 
developed after about 2-3 hrs of pulse treatment. Two of the five rats receiving 
pulses with the large area electrode at Uelectrodeo of 400 V developed an eschar at 
around the third day after pulsing, which fell off within 20 days. Such observations 
were reported during electrochemotheraphy studies (Hoffmann, 1999). The 
damaging effects seen with the large area electrode at 400V were also observed in 
controls, wherein electroporation was done without the drug, ruling out any drug-
related adverse effects. 
Sharma et al, used a large-area electrode similar to the one used in the 
above study. It was shown to produce a higher drug delivery and transdermal 
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voltage, as well as a higher current for the same Uelectrode,o• as compared to the small-
area electrode (Sharma, 2000a and b). Interestingly, histological studies showed 
that at the same transdermal voltages the large-area electrode showed fewer 
morphological changes compared to the small-area el.ectrode (Sharma, 2000b ). This 
was suggested to be due to the more uniform current distribution of the large-area 
electrode. In the morphological studies the skin was frozen immediately after 
pulsing. Changes taking place after late periods of time were not observed. In the 
study conducted here, the development of the erythema and eschar was recorded 
hours and days after pulsing. Localized joule heating could have occurred leading 
to tissue necrosis. Such observations are not uncommon and are hypothesized to 
be a function of the electrical field strength in the tissue (Zachary et al, 1990). 
Further characterization of both large and small area electrodes would be necessary 
to clearly understand the effects produced by these electrodes. Miklavcic, 1998, 
used magnetic resonance current density imaging along with finite element three-
dimensional analysis to evaluate two different types of electrochemotherapy 
electrodes. Such studies would be very useful in characterizing and designing a new 
electrode. 
A recent review by Vanbever, 1999b, suggests the use of pulse lengths 
shorter than 1 ms to reduce muscle twitching. However, muscle twitching was 
reported at 1 00 microseconds in electrochemotheraphy clinical trials (Hoffmann, 
1999). In vitro studies suggest that delivery as well as damage increases linearly 
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Figure 4.5: In vivo electroporative drug delivery in male fuzzy rats. Plasma TRZ 
concentration (y-axis) against time (x-axis) curves for various treatments. Passive delivery 
showed no detectable drug levels. Pulse conditions for both . types of electrodes were: 
applied voltage 400 V, 20 ms pulse length, 20 pulses at 10 ppm, 10% TRZ in contact only 
during pulsing(2 mins). 
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with pulse lengths and voltages (Vanbever, 1999 and Sharma, 2000a). A study 
reported in a patent, for improved electrode design for use in electroporation, an 
Uelectrode,o of 300V and 1 ms pulse length appeared to be the upper limit of tolerance 
in humans (Weaver, 1996). Zhang et al, 1999, also developed a new electrode 
design which was used to deliver vitamin C. They reported a threshold of tolerable 
sensation in human facial skin at an Uelectrode,o of 80 V and 20ms with a cream 
formulation of vitamin C, and 50 V, 2 ms with a suspension formulation. The 
improvement in drug delivery over passive delivery with these conditions was only 
marginal. Even if these parameters are taken as rough indicators of acceptable 
limits, with the small amount of drug delivered it would be difficult to make 
electroporation acceptable as an alternative means of drug delivery. We are not 
aware of any other studies which comment on the tolerable human thresholds for 
the various electrical parameters with the traditional wire and plate type electrodes 
used in electroporation. 
4.2.2 In Vivo Drug Delivery Studies : 
Figure 4.5 shows the results of the in vivo studies. The passive drug delivery 
(2 min to 20 min exposure) showed no measurable drug delivery. The 
electroporation treatment showed significant delivery. Nearly two thirds of the peak 
drug concentration (Cmax) was reached within the first 5 min. Thus, reasonably high 
drug delivery can be achieved using electroporation within a short period of time, 
just as with an intravenous injection. The larger area electrode showed higher 
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delivery compared to the small-area electrode. Although the Cmax in each case was 
similar, the time (tmax ) to reach cmax was 20 min for the small-area electrode 
compared to 6 hours for the large-area electrode at. similar Uskin,o· The half lives of 
drug delivered by electroporation were also higher than that of drug delivered by IV 
or SC. This is a case exhibiting flip-flop kinetics wherein the half-life is influenced 
more by the absorption phase than the elimination phase, a common phenomenon 
in sustained release drug delivery systems. 
Longer half-lives and tmax indicate drug depot formation within the skin after 
electroporation enhanced delivery. This observation is in agreement with previous 
reports (Prausnitz, 1993a and Vanbever, 1998a). Depot formation has been reported 
for many drugs delivered by the transdermal route (Guy, 1989 and Singh, 1996). One 
suggested mechanism is limitation of dermal blood perfusion, which could decrease 
the rate of drug absorption (Benowitz, 1992). If it is assumed that in electroporation 
the drug is delivered just below the SC of the epidermis and vascular dermis at a 
much faster rate than in passive delivery (Vanbever, 1996b and Lombry 2000), and 
if the blood flow to skin is not the limiting factor a higher delivery should produce a 
higher Cmax with the same tmax· The large area electrode delivered a larger quantity · 
of drug compared to small area electrode. Therefore, it should have recorded a 
higher Cmax but this was not seen in our study, suggesting that blood flow could be 
another factor affecting drug uptake. TRZ is a peripheral vasodilator, thus it may 
increase the blood flow to the skin. However, we cannot rule out a perfusion barrier 
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to its uptake, since one could argue that it may not increase the blood flow enough 
to eliminate perfusion limited drug uptake. 
Such a scenario was seen in iontophoretic drug delivery, which also provided 
higher levels of drug than passive diffusion in the skin for vascular uptake (Riviere, 
1991 ). Thus there could be two events happening in depot formation, initially a 
perfusion-limited drug uptake could be taking place and then as the drug level in the 
skin gets reduced, diffusion through the epidermis could be taking over which could 
be a rate limiting step. Further studies will be needed to elucidate the exact 
mechanisms involved in depot formation. 
Ultrasound (3.5 MHz, <1 W/cm2) may block follicular routes by causing a flow 
of sebum from the sebaceous glands into the follicle. Similar effects can be seen if 
the hair follicle is heated, i.e., by electric current either by low or high voltage 
application (Meiden, 1998). Thus, even blocking of newly created pathways, as in 
electroporation, is possible. This may also lead to localized heating and thus 
damage as observed with the large area electrode at Uetectrode,o of 400 V. Also this 
could explain the lower drug delivery seen here with the large area electrode at 
UelectrodeO Of 400 V rather than 250 V. 
4.2.3 Estimation of pharmacokinetic parameters : 
To estimate the pharmacokinetic parameters, TRZ was given by IV and 
subcutaneous routes. Table 4.2 shows the various estimated pharmacokinetic 
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parameters. Area Under the Curves (AUG's) were calculated by the trapezoidal rule 
and half-lives were calculated from the terminal portions of the logarithm of drug 
delivered versus time curves for the four treatments. The terminal half-lives for both 
the small-area and large-area electrodes, were higher than that of IV or 
subcutaneous injections. As explained previously, these half-lives indicate drug 
depot formation within the skin. Bioavailability for the subcutaneous injection was 
calculated from the AUC of IV and subcutaneous injections. Similarly the amount 
of drug delivered was calculated for the two electrodes using the AUG's. Around 
Table 4.2: Estimated pharmacokinetic parameters from in vivo data(± SD). 
Delivery t1/2 tmax cmax AUC Amount 
conditions (ng/ml of delivered 
(hrs) (hrs) plasma) (~g) 
IV injection 2.6 ± 0.083 11.3 ± 0.3 . 24 ± 14.5 ± 1 
(301Jg/kg) 0.35 5.24 
Subcutaneous 2.3 ± 0.33± 12.1 ± 2.94 41 ± 25 ±6.13 
injection (601Jg/kg) 1.08 0.19 10.35 
Small area 6.6 ± 0.33± 11.2 ± 4.48 90± 55± 17.96 
electrode, 400V 2.15 0.29 53.03 
Large area 10.5 ± 3.0 ± 11.3 ± 2.62 178 ± 109 ± 18.28 
electrode, 400V 3.6 1.16 57.96 
Large area 6.0 ± 6.0 ± 10.4 ± 1.14 207 ± 125 ± 23.77 
electrode, 250V 1.83 1.83 40.16 
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96% of the drug recovery was seen in the subcutaneous route, which rules out any 
significant drug metabolism in the subcutaneous tissue. In a previous in vitro study 
matching Uskin,o voltages gave similar deliveries irrespective of electrode area 
(Sharma, 2000a). However, in vivo the average amount of drug delivered by the 
large-area electrode was nearly twice that of the small-area electrode with similar 
Uskin,o· This needs further studies for clear understanding. 
4.3 Measurements of Electrical Parameters of Skin During Electroporation-
Effect of Electrode Area : 
It was seen that the uskin,O increased with increase in applied voltage keeping 
pulse length constant (Figure 4.6a). However, it decreased with an increase in pulse 
length when the applied voltage was kept constant (Figure 4.6b). 
The current density increased with increase in either applied voltage (Figure 
4.7a) or pulse length (Figure 4.7b) - with the other parameter kept constant. 
Instantaneous power density. showed an increase with applied voltage when the 
pulse length was constant (Figure 4.8) and remained nearly constant with increase 
in pulse length . The uskin,Ol initial current density and instantaneous power density 
showed an increasing trend with increasing electrode area at any given applied 
voltage and/or pulse length conditions 
However, the small-area electrode showed a lower dynamic resistance than 
the 5 or 15X coil electrodes with either increasing applied voltage and constant 
pulse length(Figure 4.9) or increasing pulse length with constant applied voltage 
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(Figure 4.1 0). This can be explained by disproportionate increase in uskin,O relative 
to current as the applied voltage and electrode area are both increased. 
Nevertheless, a smaller dynamic resistance could mean lower skin resistance or 
"more aqueous pathways". This should actually cause an increase in drug delivery, 
but no increase was observed. This could be explained by an increased 
electrophoretic component in case of the larger-area electrodes as indicated by the 
increase in instantaneous power and current density when electrode area was 
increased, since TRZ is ionized at pH 6.4. If this electrophoretic component was 
removed, drug transport with the small-area electrode could be higher or at least 
comparable with the large-area electrodes. It would be interesting to observe the 
drug transport for all three electrodes if the electrophoretic component of the 
transport was removed by making the drug unionized in the electrolyte. 
The energy density delivered to skin also increased with increasing electrode 
area at the same applied voltage (Figure 4.11 ). Pliquett et al (1996b) have proposed 
the formation and expansion of localized dissipation regions (LOR's) in skin during 
electroporation. The expansion of these LOR's was suggested to be because of 
localized joule heating. If this heat exceeds the transition temperature of the lipids 
it could lead to irreversible damage. Increasing the amount of energy delivered could 
only worsen the situation. Thus, a large-area electrode may cause more damage to 
skin than a small-area electrode at the same applied voltage. This was also 
observed in the in vivo studies. 
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4.4 In Vivo Skin Impedance Measurements : 
Measuring passive impedance of skin before and after the application of 
electroporation would give an idea of changes taking place in the skin. The change 
in real (resistive pathways) and imaginary (capacitive pathways) impedance of the 
new plot can help in developing alternate equivalent circuits for the skin for example: 
if an additional resistance element explains the new impedance plot of skin (after 
electroporation), it would mean that additional aqueous pathways had been created 
by electroporation. However, such measurements have to be done within 
microseconds after the electroporation pulse application since electroporation 
causes skin changes which are reversible in milliseconds to seconds (Piiquett, 
1995). Some such studies have already been done (Piiquett, 1995b) and no attempt 
was made here to reproduce them. However, ·in the above situation, if the 
electroporation conditions are 'harsh', they may cause irreversible changes to occur 
in skin. Thus the impedance plot after electroporation would remain altered from its 
pre-electroporation state. A return from this altered state to the pre-electroporated 
state would indicate recovery of skin, which was tested in the following experiments. 
The aim of the study was to investigate whether the parameters which were 
arrived at by in vitro optimization experiments would cause reversible changes to 
skin. And if not, what electroporative conditions would produce a complete recovery 
of skin ? Results indicated that the optimized parameters viz: twenty pulses of 20 ms 
at 1 0 ppm, Uelectrode.o of 400 V using the small area electrode did not show any 
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appreciable recovery at all, even after 24 hrs (Figure 4.12). Thus, the number of 
pulses were drastically reduced from 20 to 1 pulse and the recovery measured. 
However, even under these conditions no recovery was observed (Figure 4.13) . 
Therefore, a reduction in pulse length was carried out from 20 ms to 1 0 ms. This 
condition showed a modest .50% recovery at the end of 24 hrs (Figure 4.14}. To 
evaluate whether a further reduction in pulse length would cause complete recovery 
or not, a single electroporation pulse of 1 ms with Uelectrode,o of 400 V was delivered. 
The recovery was not 1 00%, but was similar to that following the 1 0 ms 
electroporation pulse i.e close to 50%, Figure 4.15. The large area electrode was 
also evaluated under Uelectrode,o of 400 V, 20 ms and single pulse. It did not show any 
greater recovery than with the small-area electrode under the same electrical 
conditions. 
Thus an appreciable recovery occurs only with one pulse of 1 to 10 ms, of 
Uelectrocle,o of 400 V. If we take the results of the in vitro study of TRZ delivery by 
electroporation (Sharma,2000a) into consideration, the above conditions would not 
produce any useful drug delivery. However, it would be premature to draw such 
conclusions without doing the impedance recovery studies at lower Uelectrode 0 and 
longer pulse lengths and so on. Also it is important to elucidate the exact 
relationship between impedance recovery and in vivo safety of electroporation. Even 
puncturing skin with a hypodermic needle can cause a dramatic reduction in 
resistance of skin (Prausnitz, 1999). But it is accepted that such a procedure is safe. 
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4.5 Skin Viability Assessment : 
Three electroporative conditions were tested. The results of the study were 
quite informative. As can be seen from the Figure 4.16, after electroporation with the 
one pulse of 60 ms at uelectrode,O of 500 V, and one pulse of 4 ms at uelectrode,O of 1 000 
V, the initial skin's glucose consumption was disrupted (lag phase, no lactate 
production) and then began suddenly to increase (increased lactate formation) 
compared to the control (no electroporation pulse applied). One pulse of 20 ms at 
Uelectrode,o of 400 V showed no lag phase, however, these conditions also produced 
a dramatic increase in the glucose consumption (higher lactate formation) . Overall, 
electrical pulses seemed to 'stimulate' glucose consumption. 
The primary means of glucose uptake could be through the microvasculature 
in the excised skin. Using extreme electrical conditions might cause electroporation 
of the nerves in the dermis causing a secretion of epinephrine and leading to 
vasoconstriction of the micro-vasculature. This may hinder glucose uptake, which 
possibly causes the observed lag phase in lactate formation using very 'harsh' 
electroporative conditions. The permeabilization of cell membrane is an important 
mechanism of skeletal muscle and nerve injury in electrical shock (Lee, 1995). 
In the in vivo impedance studies, an incomplete recovery of skin after 24 hrs 
was observed. Even with the "mildest" possible electrical conditions, skin recovery 
continued after 24 hrs. Similar observations were made in an in vitro experiment by 
Pliquett, 1995. Probably even the "mildest" electroporation condition causes some 
99 
damage to the lipid milieu in the skin. As a consequence of this the skin begins its 
repair process and this requires energy, ATP, which is produced by. converting 
glucose to lactose. This could explain the increase in lactate production after 
application of electroporation pulses. 
· Interestingly, calcium levels have been shown to be important for epidermal 
differentiation (Yuspa, 1989) and low extracellular levels of calcium are very 
important to trigger the repair process in the epidermis (Lee, 1992 and 1994 ). This 
was further demonstrated using sonophoresis to disrupt the calcium gradients within 
the epidermis by Menon et al, 1994. During electroporation the extracellular calcium 
could have been driven out of the epidermis due to the current passing through it. 
Such an event has been shown to occur with iontophoresis (Lee, 1998b ). This might 
lead to triggering of the repair process which involves secretion of the lamellar 
bodies requiring various synthetic processes to start in the epidermis, which in turn 
require energy supplied by the glucose utilization method. Thus electroporation may 
lead to a decrease in extracellular levels of calcium in the epidermis or disruption in 
the epidermal calcium gradient leading to a cascade of events which cause increase 
in glucose utilization in the epidermis. This could be used as an alternative 
explanation to explain the increase in lactate levels of electroporated samples 
beyond that of the control samples. However, this hypothesis needs to be further . 
investigated. A method to selectively disrupt the lipids only without affecting the 
calcium gradients and another method to selectively disrupt calcium gradients 
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without damaging the lipids and measuring glucose utilization in either case would 
possibly provide some insight into the observed trends in glucose utilization after 
electroporation. Such an experiment could also help in explaining the mechanism 
of wound healing by use of electrical stimuli (Fieischli, 1997). 
Lee et al (1995), have suggested the denaturation of ion-channel proteins 
due to electroporation of cell membranes in electric shock, leading to a loss of ion 
gradient across the membrane. This would lead to higher work by the electroporated 
cells to maintain the ion gradient and use more ATP, which in turn would result in 
increased utilization of glucose and formation of higher lactate. 
The damage could be occurring in two steps, initially, at lower electric field 
strengths only the extracellular calcium levels could be affected but as the field 
strength increases the viable cells below the SC could get electroporated leading 
to the damage to ion-channel proteins and thus increase in energy utilization. The 
extent of damage may determine the time taken for recovery of the skin. 
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5.0 Conclusions : 
The electrical parameters selected by the in vitro optimization experiments for 
the electroporative delivery of TRZ were, uelectrode,O 400 v ' 20 ms, 20 pulses at the 
rate of 1 0 ppm. The in vivo studies demonstrated that electroporation mediated drug 
delivery was advantageous compared to passive diffusion and the parameters 
chosen from in vitro optimization were safe and effective. At the same Uskin.o the large 
area electrode showed a higher TRZ delivery than the small area electrode 
conclusively proving that the large area electrode had better in vivo drug delivery 
compared to small area electrode, consistent with the in vitro studies. 
The pulse length used in the above in vivo study, 20 ms, was considerably 
less than 300 ms used by Vanbever et al 1998a, but. it was much higher than the 
pulse length (-1 ms) used by Prausnitz et al1993a. However, muscle twitching and 
vocalization were observed in all studies and under all electrical conditions. 
Increasing the Ue,ectrode,o to 400 V with the larger area electrode caused unacceptable 
skin damage. Edema and later eschar formation were observed. The reasons could 
be attributed to thermal and non-thermal effects of electrical trauma. 
The drug distribution in skin after electroporation study did not show a non-
uniformity of drug delivery in the three different pieces of the exposed skin with 
either a straight wire electrode or a coiled wire electrode. If the assumption that 
"drug distribution within the skin is proportional to the electric field it is exposed to", 
is correct, then it could be concluded that the electric field produced by both types 
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of electrodes is uniformly distributed on the exposed skin. 
In the in vivo recovery of impedance studies complete recovery at 24 hrs was 
not observed under any pulsing conditions. Skins impedance recovery at 24 hrs after 
pulsing improved with decreasing pulse lengths and lesser number of pulses. These 
observations are consistent with the previous observations. In the previous studies 
·higher applied voltages and longer pulse lengths led to a irreversible or prolonged 
increase in drug delivery even after pulsing was stopped. However at lower applied 
voltages and shorter pulses the drug delivery returned back to the pre-pulsing rate 
very quickly. Meaning therefore, that recovery of skin was faster with lower applied 
voltages and shorter pulses. By comparison in vivo impedance gave similar results 
and hence, could be considered a useful tool to gauge the safety of electroporation. 
Using higher Uelectrode 0 to pulse the skin caused a delay in initial glucose 
utilization, due to possible permeabilization of the nerves releasing epinephrine and 
causing vasoconstriction. All the pulsed skin samples showed higher cumulative 
lactate formation (glucose utilization) at the end of24 hrs. Electroporation could lead 
to the disruption/destruction of lipids and changes in extracellular calcium gradient 
which triggered the cells to increase glucose uptake giving energy to the cells to · 
replace/restore the lipid/lipid ordering and to restore the calcium gradient. Combined 
together we could infer that electroporation does cause unwanted changes in the 
viable epidermis and dermis. 
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6.0 Future Perspectives: 
The results of this study conclusively prove that electroporation is a feasible 
method to deliver drugs systemically. Moreover, using various combinations of 
electrical parameters might be possible to alter the drug levels delivered. 
Muscle twitching and vocalization were observed at all electrical pulse 
conditions used. Using side-by-side type of electrodes in electroincorporation 
studies (Sec 1.5.4.5.4) has been suggested to reduce sensations, however, further 
in vivo studies need to be done. Ultimately, electroporation technique would be less 
likely successful as a simple alternative to the hypodermic needle if the pulsing 
causes discomfort or unacceptable sensations like those of needle puncture. 
No gross morphological changes were observed with Uskin,o of -1 OOV. 
However, at higher Uskin 0 delayed edema and eschar formation were observed. In 
vivo impedance recovery experiments showed that the conditions which deliver the 
drug effectively, do not cause recovery of impedance within 24 hrs. The significance 
and cause of these long lasting and delayed changes would have to be determined 
in future studies. 
The glucose utilization studies showed that electroporation does cause 
biochemical changes within the skin as noticed by increased lactate production in 
all electroporated samples. With certain "harsh" electrical pulse conditions a lag 
phase was also observed. It is speculated that electroj:>oration causes the changes 
in two stages. Initially the changes in the lipid milieu and calcium gradients occurring 
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result in increased glucose utilization for repair or replacement of the damaged SC 
lipids. In the second stage when the electrical conditions are strong enough to 
permeabilize the cells and nerves in the lower epidermal and dermal layers, the 
increased glucose utilization would occur for maintaining the ion gradient within the 
cells. Experiments to evaluate changes in calcium gradient and changes in the cell 
membrane proteins on certain electroporation conditions, need to be designed to 
prove the above hypothesis. 
The cause of delayed reactions in the skin after electroporation has to be 
found and methods to avoid it have to be established. Further innovation in 
electrode design and/or combination of enhancement techniques need to be 
evaluated to reduce physical discomfort during the drug delivery. These factors 
could directly affect the tolerability of electroporation pulses and thus its 
acceptability as a non-invasive and safe method for drug delivery in humans. 
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Appendix I 
Calculation of area of three electrodes 
Diameter of silver wire= d = 0.5 mm = 0.05 em 
:. Radius of wire used for all three electrodes = (r) = 0.025 em 
L = length of the wire used 
1 . Small area electrode ( 1 X) 
( L = 1.3 em) 
Area = 2nrL + nr-2 
= 0.2042 + 0.0019635 
= 0.2061cm2 
2. Large area electrode (5X) 
(L = 6.5 em) 
Area = 2nrL + nr-2 
= 1.021 + 0.0019635 
= 1.023 cm2 
3. Large area electrode ( 15X) 
(L = 19.5 em) 
Area = 2nrL + nr-2 
= 3.063 + 0.0019635 
= 3.065 em 
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